HIV vaccines and methods of using

Abstract

To provide HIV vaccines and methods of using.SOLUTION: Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and / or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.SELECTED DRAWING: None

Description

[Technical Field]

[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application Nos. 63 / 137,521, filed January 14, 2021, 63 / 149,820, filed February 16, 2021, and 63 / 170,900, filed April 5, 2021, which are incorporated by reference in their entireties for all purposes. Sequence Listing

[0002] This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy, created on December 12, 2021, is named 1355-WO-PCT.txt and is 512,244 bytes in size. [Background technology]

[0003] HIV remains one of the leading causes of mobility and mortality globally, with over 38 million infections and 690,000 deaths worldwide in 2019 (UNAIDS.Fact Sheet-World AIDS Day 2020.unaidsorg / en / resources / fact-sheet.2020). Over the past 30 years, significant improvements have been made in the treatment of HIV. The development of highly active antiretroviral therapy has improved survival rates for people living with HIV and reduced morbidity from HIV-associated immunosuppression and opportunistic infections (Johnson, et al., PLoS Med. 2013;10(4):e1001418; May, et al., AIDS. (2014) 28(8):1193-202; Rodger, et al., AIDS. (2013) 27(6):973-9; Samji, et al., PLoS One. (2013) 8(12):e81355). In recent years, antiretroviral treatment (ART) regimens have been simplified to long-acting oral agents, once-daily pills, and in the near future, injectable treatments (Swindells, et al., N Engl J Med. (2020) 382(12): 1112-23; Orkin, et al., N Engl J Med. (2020) 382(12): 1124-35; Link, et al., Nature. (2020) 584(7822): 614-8). Despite these advances in treatment, to date, there have been only two well-documented cases of cure, both of which required severe immunosuppression and bone marrow transplantation (Gupta, et al., Lancet HIV. (2020) 7(5): e340-e7; Hutter, et al., N Engl J Med. (2009) 360(7):692-8). Unlike many self-limited infections, the HIV virus integrates itself into the host genome, establishing latency in resting memory CD4+ T cells (Eisele, et al., Immunity. (2012) 37(3):377-88). These cells form a latent HIV reservoir that cannot be eliminated by standard antiretroviral therapy. Reservoir cells are also protected from immune surveillance and clearance mechanisms because they do not express viral antigens that enable them to evade recognition and clearance by cytotoxic T cells. The reservoir is long-lived, and viral rebound is observed after ART discontinuation, despite a detectable decrease in reservoir size (Henrich, et al., Ann Intern Med. (2014) 161(5):319-27; Henrich, et al., J Infect Dis. (2013) 207(11):1694-702). Activation of the reservoir with latent infection-reactivating agents must be coupled with an effective mechanism to stimulate cytotoxic T cells and eliminate infected reservoir cells (Ait-Ammar, et al., Front Microbiol. (2019) 10:3060; Mothe, et al., Front Immunol. (2020) 11:823; Fidler, et al., Lancet. (2020) 395(10227):888-98). Therapeutic vaccines designed to generate antigen-specific effector T cell responses may be a further component of an HIV cure strategy.

[0004] T cell vaccines hold considerable promise in therapeutic areas such as oncology. High levels of tumor-infiltrating CD8+ lymphocytes are associated with favorable prognosis in several cancers, spurring considerable interest in developing vaccines capable of inducing tumor-specific cytotoxic CD8+ T cells. While previous approaches have met with limited success (Rosenberg, et al., Nature Medicine. (2004) 10(9):909-15), the use of novel delivery platforms and improved methods in antigen discovery and immune modulation have shown some promise (Ott, et al., Nature. (2017) 547(7662):217-21). Similarly, T cells play a key role in controlling HIV viremia. Antigen-specific T cells generated during acute HIV infection are involved in driving the initial decline in viremia (Borrow, et al., J Virol. (1994) 68(9):6103-10; Koup, et al., J Virol. (1994) 68(7):4650-5). Human long-term non-progressors infected with HIV, or elite controllers, are characterized by having strong and effective antigen-specific T cell responses. In SIV infection (a non-human primate model of human HIV infection), antigen-specific T cells generated naturally or by vaccination have been associated with viral control (Schmitz, et al., J Virol. (1994) 68(9):6103-10; Koup, et al., J Virol. (1994) 68(7):4650-5). al., Science. (1999) 283(5403):857-60; Jin, et al., J Exp Med. (1999) 189(6):991-8). Despite this data, prophylactic T cell vaccines have had limited success in inducing T cell responses of limited scope or efficacy (Buchbinder, et al., Lancet. (2008) 372(9653):1881-93; Janes, et al., J Infect Dis. (2013) 208(8):1231-9; Excler, et al., Curr Opin HIV AIDS. (2016) 11(6):607-13). Therapeutic vaccine trials using T cell vaccines have also shown limited efficacy (Mothe, et al., Front Immunol. (2020) 11:823; Colby, et al., Nature Medicine. (2020) 26(4):498-501). These trials have used viral vectors, such as adenovirus (human and chimpanzee) and modified vaccinia Ankara (MVA) virus, with full-length viral antigens or shorter constructs (Barouch, et al., Lancet. (2018) 392(10143):232-43; Mothe, et al., EClinical Medicine. (2019) 11:65-80). Data from these trials suggest that the range of antigen-specific T cells generated after vaccination is narrow. Although these vaccine-induced T cells secrete IFN-γ in standard ELISpot assays, the lack of demonstrated efficacy suggests that these T cells may not possess full cytotoxic activity.

[0005] Immunogen design is a component of any therapeutic HIV vaccine to target conserved regions and generate appropriate antigen-specific responses with cytotoxic activity. Natural infection has demonstrated that immune responses tend to focus on highly immunodominant variable regions within HIV, such as those in the HIV envelope or Nef, or those in HIV Gag (Addo, et al. J Virol. (2003) 77(3):2081-92; Betts, et al. J Virol. 2001; 75(24):11983-91). These responses generate T cells from which the virus can rapidly escape without fitness cost (Liu, et al. J Virol. (2006) 80(19):9519-29). An effective HIV vaccine must avoid these regions and drive the establishment of de novo responses that focus the immune response on conserved regions of the virus that are required for maintaining viral function. Previous HIV vaccines have primarily focused on designing immunogens that provide universal coverage by addressing the overall HIV viral diversity, either generating full-length sequences or adapting algorithms to generate constructs of conserved regions (Körber, et al., Hum Vaccin Immunother. (2020) 16(3):713-722; Fischer, et al., Nature Medicine. (2007) 13(1):100-6). All of these approaches primarily evaluate consensus sequences that assess interpatient variability to determine conserved regions and are concatenated to provide overall sequence coverage. However, several circulating quasi-species exist within HIV-infected individuals. Some of these viral quasispecies are generated as a result of T cell pressure and reflect existing viral escape pathways that should result in the emergence of a virus-directed T cell response (Liu, et al., J Virol. (2006) 80(19):9519-29; Korber, et al., 2020, supra; Price, et al., Proc Natl Acad Sci U S A. (1997) 94(5):1890-5). The failure of previous vaccine targeting of conserved regions to consider quasispecies, along with the identification of highly conserved immunogenic regions, may partially explain their limited efficacy (Hanke, et al., Expert Rev Vaccines.(2019)18(10):1029-41). [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] UNAIDS.Fact Sheet-World AIDS Day 2020.unaidsorg / en / resources / fact-sheet.2020 [Non-patent document 2] Johnson,et al.,PLoS Med.2013;10(4):e1001418 [Non-patent document 3] May, et al., AIDS.(2014)28(8):1193-202 [Non-patent document 4] Rodger,et al.,AIDS.(2013)27(6):973-9 [Non-patent document 5] Samji,et al.,PLoS One.(2013)8(12):e81355 Summary of the Invention [Means for solving the problem]

[0007] Fusion polypeptides are provided that include multiple polypeptide segments of one or more Human Immunodeficiency Virus-1 (HIV-1) proteins encoded by two or more HIV genes selected from gag, pol, and nef. In some embodiments, the multiple polypeptide segments include or consist of polypeptide segments encoded by the HIV-1 genes pol and nef, but do not include polypeptide segments encoded by the HIV-1 genes env, tat, rev, vpr, vif, and / or vpu. In some embodiments, the multiple polypeptide segments include or consist of polypeptide segments encoded by the HIV-1 genes gag, pol, and nef, but do not include polypeptide segments encoded by the HIV-1 genes env, tat, rev, vpr, vif, and / or vpu. In some embodiments, the multiple polypeptide segments are derived from conserved regions in a population of viral proteome sequences. In some embodiments, the conserved regions are greater than 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% conserved among HIV-1 species in patient populations. In some embodiments, the conserved regions are conserved among one or more of HIV-1 clades A-K, e.g., one or more of clades A, B, C, D, and G, or recombinant forms of one or more of HIV-1 clades A-K, and combinations thereof. In some embodiments, the fusion polypeptide comprises at least four and up to six polypeptide segments, e.g., four, five, or six polypeptide segments.In some embodiments, each polypeptide segment is at least 10 amino acids in length and up to about 225 amino acids in length, e.g., at least 10 amino acids in length and up to 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 , 38, 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220 or 225 amino acids in length. In some embodiments, the total length of the fusion polypeptide comprises at least about 330 amino acids and up to about 505 amino acids (excluding the signal peptide) or up to about 550 amino acids (including the signal peptide), e.g., at least about 330 amino acids and up to about 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, or 550 amino acids. In some embodiments, the total length of the fusion polypeptide is 550 amino acids or less (with signal peptide) or 505 amino acids or less (without signal peptide), e.g., 545, 540, 535, 530, 525, 520, 515, 510, 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355, 350, 345, 340, 335, or 330 amino acids or less. In some embodiments, the total length of the fusion polypeptide comprises at least 350 amino acids and at most 385 amino acids, for example, at least 350 amino acids and at most 365 amino acids.In some embodiments, the total length of the fusion polypeptide comprises at least 390 amino acids and at most 395 amino acids. In some embodiments, each polypeptide segment comprises or consists of one or more predicted T cell epitopes. In some embodiments, the fusion polypeptide comprises three or more predicted T cell epitopes, e.g., four, five, six or more predicted T cell epitopes. In some embodiments, the fusion polypeptide comprises one or more polypeptide segments that bind to or are presented by one or more human HLA class I alleles (e.g., 1, 2, 3, 4, 5 or 6 alleles), e.g., within a single subject or among multiple patients. In some embodiments, the fusion polypeptide comprises at least one polypeptide segment that binds to or is presented by one or more human HLA class I alleles (e.g., 1, 2, 3, 4, 5 or 6 alleles), e.g., within a single subject or among multiple patients. *

[0201] The fusion polypeptide comprises one or more polypeptide segments that bind to or are presented by HLA class I molecules. In some embodiments, the fusion polypeptide comprises one or more polypeptide segments that are intracellularly processed and presented by one or more human HLA class II alleles (e.g., 1, 2, 3, 4, 5, or 6 alleles), e.g., within a single subject. In some embodiments, one or more polypeptide segments are adjacent to or fused to adjacent segments. In some embodiments, one or more of the polypeptide segments are linked to adjacent segments by one or more peptide linkers. In some embodiments, the one or more peptide linkers are selected from one or more of polyalanine, polyglycine, Gln-Glu-Glu (QEE), lysine (L), isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL), Leu-Ile-Lys (LIK), Pro-Pro-Val (PPV), Ser-Glu-Gly (SEG), a cleavable linker, a flexible linker, a rigid linker, and combinations thereof. In some embodiments, the flexible linker is selected from Gln-Glu-Glu (QEE) (SEQ ID NO: 51), lysine (L), isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL) (SEQ ID NO: 52), Leu-Ile-Lys (LIK) (SEQ ID NO: 53), Pro-Pro-Val (PPV) (SEQ ID NO: 54), and Ser-Glu-Gly (SEG) (SEQ ID NO: 55). In some embodiments, the flexible linker comprises a polyalanine or polyglycine linker, e.g., comprising or consisting of two or three consecutive alanine residues, e.g., AA, AAA (SEQ ID NO: 48), AAY (SEQ ID NO: 49), or AAX (where X is any amino acid (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Y)) (SEQ ID NO: 50). In some embodiments, the flexible linker comprises or consists of GG, GGS (SEQ ID NO: 57), GSG (SEQ ID NO: 58), or GGGS (SEQ ID NO: 59).In some embodiments, the cleavable linker is selected from a 2A cleavable peptide (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A), and Thosea asigna virus (T2A)), a furin recognition / cleavage sequence (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62)), and combinations, derivatives, or variants thereof. In some embodiments, the cleavable linker comprises or consists of a furin recognition / cleavage site selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62). In some embodiments, the cleavable linker is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 1109%, 1110%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%, 164%, 165%, 166%, 167%, 168%, 169%, 170%, 171%, 172%, 173%, 174%, 175%, 176%, 177%, 178%, 179%, 180%, 181%, 182%, 183%, 184%, 185%, 186%, 187%, 188%, 189%, 189%, 8%, or at least 99% identical thereto, and comprising or consisting of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67). In some embodiments, the fusion polypeptide comprises two, three, four, five, six, or more of the polypeptide segments, including Gag 1-53, Gag 147-369, Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 586-606, Pol 683-708, Pol 747-827, Pol 840-909, Pol 840-920, Pol 840-921, Pol 840-922, Pol 840-923, Pol 840-924, Pol 840-925, Pol 840-926, Pol 840-927, Pol 840-928, Pol 840-929 ... or consisting of amino acid residues corresponding to Gag, Pol and Nef 932-1003, Nef 64-76, Nef 64-99 or Nef 117-148, where the amino acid position numbers of Gag, Pol and Nef correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the fusion polypeptide does not include any polypeptide segment corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or a fragment or subsequence thereof, where the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, the fusion polypeptide does not comprise a polypeptide segment having the amino acid sequence of any one of SEQ ID NOs: 35-47, or a fragment or subsequence thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 35-47, or a fragment or subsequence thereof. In some embodiments, the fusion polypeptide comprises two, three, four, five, six, or more polypeptide segments selected from SEQ ID NOs: 4-33.In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments, where the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NOs: 1, 2, and 3, respectively: (a) amino acid residues corresponding to Gag 1-53, Gag 147-369, Pol 683-708, and Nef 117-148; (b) amino acid residues corresponding to Pol 56-117, Pol 129-320, Pol 367-431, and Nef 64-99; (c) amino acid residues corresponding to Pol 542-606, Pol 747-827, Pol 840-920, Pol 932-1003, and Nef 64-99; (d) amino acid residues corresponding to Gag 1-53, Gag 147-369, Pol 683-708, Pol 747-827, Pol 932-1003, and Nef 64-99; (e) amino acid residues corresponding to Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 932-1003 and Nef 64-99; (f) Gag 147-369, Pol 586-606. (g) Amino acid residues corresponding to Pol 683-708 and Pol 840-920, (g) Pol 129-320, Pol 747-827, Pol 932-1003, and Nef or (h) amino acid residues corresponding to Gag: 147-369, Pol 747-827, Pol 840-909, and Nef 64-76. In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments: (a) a sequence segment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 4, 6, 18, and 32, or SEQ ID NOs: 4, 6, 18, and 32, respectively; (b) a sequence segment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 5, 7, 19, and 33, or SEQ ID NOs: 5, 7, 19, and 33, respectively; (c) sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 8, 10, 12, and 30, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 8, 10, 12, and 30, respectively. (d) sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 9, 11, 13, and 31, respectively; (e) sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, or 99% identical to SEQ ID NOs: 14, 20, 24, 26, and 30, respectively; (f) a sequence segment that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 21, 25, 27 and 31, or a sequence segment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 21, 25, 27 and 31, respectively; (g) a sequence segment that is 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 4, 6, 18,20, 24 and 32, or SEQ ID NOs: 4, 6, 18, 20, 24 and 32, respectively; (h) sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 5, 7, 19, 21, 25 and 33, or SEQ ID NOs: 5, 7, 19, 21, 25 and 33, respectively; (i) sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 10, 12, 14, 26 and 30, or SEQ ID NOs: 8, 10, 12, 14, 26 and 30, respectively; (j) sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 9, 11, 13, 15, 27 and 31, or SEQ ID NOs: 9, 11, 13, 15, 27 and 31, respectively. (k) sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 16, 18 and 24, respectively; (l) sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 17, 19 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 17, 19 and 25, respectively; (m) SEQ ID NOs: 10, 20, 26 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to SEQ ID NOs: 10, 20, 26 and 28, respectively;(n) a sequence segment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 21, 27 and 29, or SEQ ID NOs: 11, 21, 27 and 29, respectively; (o) a sequence segment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 6, 20, 22 and 28, or SEQ ID NOs: 6, 20, 22 and 28, respectively. (p) sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, or SEQ ID NOs: 7, 21, 23 and 29, respectively; (q) sequence segments that are at least 80% identical to SEQ ID NOs: 6, 16, 18 and 24, or SEQ ID NOs: 6, 16, 18 and 24, respectively; (r) sequence segments that are 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 17, 19 and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, or a sequence segment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 10, 20, 26 and 28, respectively; or (t) SEQ ID NOs: 11, 21, 27 and 29, or a sequence segment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to SEQ ID NOs: 11, 21, 27 and 29, respectively;In some forms, the fusion polypeptide comprises or consists of the following polypeptide segments, in N-terminal to C-terminal order, optionally linked or connected by one or more linkers: SEQ ID NOs: 6, 4, 18, and 32, or sequence segments at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 7, 5, 33, and 19, or SEQ ID NOs: sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 12, 30, 8 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 12, 30, 8 and 10, respectively; Sequence segments SEQ ID NOS: 14, 26, 20, 30, and 24 that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOS: 9, 31, 13, and 11, respectively; sequence segments which are 1%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 21, 27 and 25, or sequence segments which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 21, 27 and 25, respectively; sequence segments which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 32, 18, 4 and 6, respectively;sequence segments that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 33, 5 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 33, 5 and 19, respectively, SEQ ID NOs: 8, 30, 12 and 10, or SEQ ID NOs: 8, 30; 12 and 10, respectively, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 13, 31, 9 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 13, 31, 9 and 11, respectively, sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to sequence numbers 26, 30, 14, 20 and 24, or SEQ ID NOs: 26, 30, 14, 20 and 24, respectively; sequence numbers 31, 27, 15, 25 and 21; or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to sequence numbers 31, 27, 15, 25 and 21, respectively; 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 4, 20, 18 and 32, or SEQ ID NOs: 24, 6, 4, 20, 18 and 32, respectively;82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、 , 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 5, 25, 33 and 19, or to SEQ ID NOs: 7, 21, 5, 25, 33 and 19, respectively; sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 30, 14, 12, 26 and 10, or to SEQ ID NOs: 8, 30, 14, 12, 26 and 10, respectively; , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 12, 30, 26, 14 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 8, 12, 30, 26, 14 and 10, respectively, SEQ ID NOs: 9, 13, 31, 27, 15 and 11, or SEQ ID NOs: 9, 13, 31, 27, 15 and 11, respectively; sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 20, 32, 24, 4, 6 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% identical to SEQ ID NOs: 20, 32, 24, 4, 6 and 18, respectively; , 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 25, 19, 5, 33 and 21, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 30, 12, 14, 8 and 10, or sequence segments that are at least 80%, 81%, 82% identical to SEQ ID NOs: 26, 30, 12, 14, 8 and 10, respectively;sequence segments SEQ ID NOs: 15, 31, 9, 27, 13 and 11 which are 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or sequence segments SEQ ID NOs: 24, 6, 16 and 18 which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 15, 31, 9, 27, 13 and 11, respectively; or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 24, 6, 16 and 18, respectively; SEQ ID NOs: 7, 19, 17 and 25; or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 19, 17 and 25, respectively. a sequence segment, SEQ ID NO: 7, 25, 17, and 19, or a sequence segment, SEQ ID NO: 7, 25, 17, and 19, which is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a sequence segment, SEQ ID NO: 24, 16, 6, and 18, or SEQ ID NO: 24, 16, 6, and 18, respectively; 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 20, 10 and 28, or to SEQ ID NOs: 26, 20, 10 and 28, respectively;Sequence segments that are 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 10, 20 and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 26, 10, 20 and 28, respectively, SEQ ID NOs: 11, 27, 21 and 29, or are sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 11, 27, 21 and 29, respectively; or are sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 6, 20 and 28, respectively; Sequence segments that are 5%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 23, 7, 21 and 29, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 22, 20, 6 and 28 ... respectively. 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, or a sequence segment that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 7, 21, 23 and 29, respectively. In some embodiments, the fusion polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or any one of SEQ ID NOs: 70-101, 105-112,or consisting of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of 200-209, 222-223, and 227. In some embodiments, the fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223.

[0008] Also provided are multiple fusion polypeptides comprising at least a first fusion polypeptide and a second fusion polypeptide, wherein the first and second fusion polypeptides are independently selected from the fusion polypeptides described above and herein. In some embodiments, the multiple fusion polypeptide comprises or consists of the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively. fusion polypeptides, SEQ ID NOs: 72 and 73, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; SEQ ID NOs: 74 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; fusion polypeptides that are 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 76 and 77, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively;fusion polypeptides that are 98% or 99% identical, SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 86 and 87, or any one of SEQ ID NOs: 86 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 88 and 89, or any one of SEQ ID NOs: 88 and 89, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 85, or any one of SEQ ID NOs: 82 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 86, or any one of SEQ ID NOs: 82 and 86, respectively; fusion polypeptides, SEQ ID NOs: 82 and 88, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; or fusion polypeptides, SEQ ID NOs: 83 and 87, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87; or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. fusion polypeptides which are SEQ ID NOs: 88 and 87, or fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; SEQ ID NOs: 84 and 88, or fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, or SEQ ID NOs: 85 and 101, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, or SEQ ID NOs: 85 and 101, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively;fusion polypeptides that are 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 94 and 95, or to any one of SEQ ID NOs: 94 and 95, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 96 and 97, or to any one of SEQ ID NOs: 96 and 97, respectively; fusion polypeptides, SEQ ID NOs: 94 and 96, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; or fusion polypeptides, SEQ ID NOs: 95 and 97, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively. fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; SEQ ID NOs: 220 and 221; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively. fusion polypeptides that are identical to SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;a fusion polypeptide that is 94%, 95%, 96%, 97%, 98% or 99% identical, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 98 and 99, or any one of SEQ ID NOs: 98 and 99, respectively; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 100 and 101, or any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the composite fusion polypeptide comprises or consists of, in N-terminal to C-terminal order, the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; 2%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 72 and 73, or to any one of SEQ ID NOs: 72 and 73, respectively, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or fusion polypeptides, SEQ ID NOs: 73 and 72, which are 99% identical, or fusion polypeptides, SEQ ID NOs: 74 and 75, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively, SEQ ID NOs: 75 and 74, or at least 8% identical to any one of SEQ ID NOs: 75 and 74, respectively; fusion polypeptides, SEQ ID NOs: 76 and 77, that are 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 76 and 77, or fusion polypeptides, SEQ ID NOs: 77 and 76, or SEQ ID NO: 7, that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; 79 and 78, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively; SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively;Fusion polypeptides that are 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 83 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 85 and 84, or to any one of SEQ ID NOs: 85 and 84, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 86 and 87, or to any one of SEQ ID NOs: 86 and 87, respectively; fusion polypeptides, SEQ ID NOs: 87 and 86, which are 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; fusion polypeptides, SEQ ID NOs: 88 and 89, or SEQ ID NOs: 88 and 89, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; 9, SEQ ID NOs: 89 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively;fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 85, or any one of SEQ ID NOs: 82 and 85, respectively; SEQ ID NOs: 85 and 82, or any one of SEQ ID NOs: 85 and 82, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, Fusion polypeptides that are 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, SEQ ID NOs: 88 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively. fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 83 and 87, or any one of SEQ ID NOs: 83 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 87 and 83, or any one of SEQ ID NOs: 87 and 83, respectively;Fusion polypeptides that are 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 85 and 87, or to any one of SEQ ID NOs: 85 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 87 and 85, or to any one of SEQ ID NOs: 87 and 85, respectively. fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively. fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively;Fusion polypeptides that are 98% or 99% identical, SEQ ID NOs: 89 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively, SEQ ID NOs: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. fusion polypeptides that are 1%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 101 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; fusion polypeptides that are 1%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, or at least 80%, 81%, 82%, 83%, 84% identical to any one of SEQ ID NOs: 90 and 91, respectively; , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 91 and 90, or to any one of SEQ ID NOs: 91 and 90, respectively; fusion polypeptides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 92 and 93, or to any one of SEQ ID NOs: 92 and 93, respectively. fusion polypeptides, SEQ ID NOs: 93 and 92, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or fusion polypeptides, SEQ ID NOs: 94 and 95, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; and 94, or SEQ ID NOs: 95 and 94, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; 97 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, respectively; 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 94, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 97 and 95, or to any one of SEQ ID NOs: 97 and 95, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 220 and 221, or to any one of SEQ ID NOs: 220 and 221, respectively;fusion polypeptides that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively, SEQ ID NOs: 98 and 100, or SEQ ID NOs: 98 and 100, SEQ ID NOs: 100 and 98, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively. 99 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively; 97%, 98% or 99% identical to SEQ ID NOs: 98 and 99, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively;fusion polypeptides that are 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% to any one of SEQ ID NOs: 100 and 101, respectively; , 98% or 99% identical, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 101 and 100, or any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are linked or connected by a cleavable linker. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are linked or connected by a cleavable linker selected from a 2A cleavable peptide (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A), and Thosea asigna virus (T2A)), a furin recognition / cleavage sequence (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62)), and combinations, derivatives, or variants thereof. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are linked or connected by a furin recognition / cleavage site selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62). In some embodiments, the first fusion polypeptide and the second fusion polypeptide comprise or consist of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67), orAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67) are linked or connected by a 2A-cleavable peptide having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67). In some embodiments, the composite fusion polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or the amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227. In some embodiments, the composite fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223.

[0009] Regarding further embodiments of fusion polypeptides and multiple fusion polypeptides, in some embodiments the fusion polypeptide or multiple fusion polypeptide further comprises an N-terminal signal peptide or leader sequence, in some embodiments the signal peptide or leader sequence is derived from a source protein selected from a serum protein, a cytokine, a chemokine, a chaperone protein, an invariant protein, and a protein that targets proteins to the lysosomal compartment. In some embodiments, the signal peptide or leader sequence is derived from a source protein selected from the group consisting of colony-stimulating factor 2 (CSF2, GM-CSF), tissue-type plasminogen activator (PLAT, t-PA), CC motif chemokine ligand 7 (CCL7, MCP-3), C-X-C motif chemokine ligand 10 (CXCL10, IP-10), catenin beta 1 (CTNNB1), CD74 (p33; DHLAG; HLADG; Ia-gamma, invariant chain), serum albumin (ALB), polyubiquitin B / C (UBB / UBC), calreticulin (CALR), vesicular stomatitis virus G protein (VSV-G), lysosomal-associated membrane protein 1 (LAMP-1), and lysosomal-associated membrane protein 2 (LAMP-2). In some embodiments, the signal peptide or leader sequence is selected from the amino acid sequence of any one of SEQ ID NOs: 115-126, or an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 115-126. In some embodiments, the fusion polypeptides and / or composite fusion polypeptides are recombinantly produced or chemically synthesized. In some embodiments, the fusion polypeptides and / or composite fusion polypeptides are capable of inducing, enhancing, or stimulating an immune response in humans. In some embodiments, the fusion polypeptides and / or composite fusion polypeptides are capable of inducing, enhancing, or stimulating an immune response against HIV-1 in humans.In some embodiments, the fusion polypeptides and / or composite fusion polypeptides are capable of inducing, promoting, or stimulating the proliferation and / or activation of one or more cell types selected from monocyte-derived dendritic cells (DCs), CD8+ T cells, and CD4+ T cells.

[0010] Further provided are polynucleotides encoding one or more fusion polypeptides or composite fusion polypeptides as described above and herein. In some embodiments, the polynucleotide comprises cDNA, mRNA, self-amplifying RNA (SAM, saRNA), self-replicating RNA, or self-amplifying replicon RNA (RepRNA). In some embodiments, the polynucleotide comprises a self-replicating or self-amplifying alphavirus replicon. In some embodiments, the polynucleotide comprises the nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the polynucleotide comprises the nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226. Further provided are expression cassettes comprising one or more polynucleotides described herein operably linked to one or more regulatory sequences, e.g., promoters. In some embodiments, the polynucleotides are operably linked to and under the control of a constitutive promoter. In some embodiments, the promoter is selected from a CMV promoter, a CAG promoter, and an EF1a promoter.

[0011] Also provided are lipoplexes, e.g., lipid nanoparticles (LNPs), having, for example, the amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227. The present invention also includes one or more polynucleotides described herein that encode one or more polypeptides, such as one or more polynucleotides comprising the nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226.In some embodiments, lipoplexes, e.g., lipid nanoparticles (LNPs), comprise one or more polypeptides described herein, e.g., encoding one or more polypeptides having the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223. and one or more polynucleotides comprising the nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226.

[0012] Also provided are vectors comprising one or more polynucleotides and one or more expression cassettes. In some embodiments, the vectors comprise or consist of one or more polynucleotides encoding one or more fusion polypeptides comprising, in N-terminal to C-terminal order, the following polypeptide segments, optionally linked or connected by one or more linkers: SEQ ID NOs: 6, 4, 16, and 26, and SEQ ID NOs: 7, 5, 27, and 17; SEQ ID NOs: 12, 24, 8, and 10, and SEQ ID NOs: 9, 25, 13, and 11; SEQ ID NOs: 14, 22, 18, 24, and 20; and SEQ ID NOs: 15, 25, 19, 23, and 24. 1, SEQ ID NOs: 26, 16, 4, and 6, and SEQ ID NOs: 7, 27, 5, and 17, SEQ ID NOs: 8, 24, 12, and 10, and SEQ ID NOs: 13, 25, 9, and 11, SEQ ID NOs: 22, 24, 14, 18, and 20, and SEQ ID NOs: 25, 23, 15, 21, and 19, SEQ ID NOs: 20, 6, 4, 18, 16, and 26, and SEQ ID NOs: 7, 19, 5, 21, 27, and 17, SEQ ID NOs: 8, 24, 14, 12, 22, and 10, and SEQ ID NOs: 9, 13, 25, 23, 15, and 11, SEQ ID NOs: 18, 26, 20, 4, 6, and 16, and SEQ ID NOs: 7, 21, 17, 5, 27, and 19, SEQ ID NOs: 22, 24, 12, 14, 8, and 10, and SEQ ID NOs: 15, 25, 9, 23, 13, and 11, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 7, 21, 5, 25, 33, and 19, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 8, 30, 14, 12, 26, and 10, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 6, 20, 4, 24, 32, and 18, and SEQ ID NOs: 8, 12, 30, 26, 14, and 10, SEQ ID NOs: 7, 21, 5, 25, 33, and 19, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 20, 32, 24, 4, 6, and 18, and SEQ ID NOs: 26, 30, 12, 14, 8, and 10, SEQ ID NOs: 7, 25, 19, 5, 33, and 21, and SEQ ID NOs: 15, 31, 9, 27, 13, and 11, SEQ ID NOs: 24, 6, 16, and 18,and SEQ ID NOs: 26, 20, 10, and 28, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 10, 20, and 28, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 7, 25, 17, and 19, SEQ ID NOs: 7, 19, 17, and 25, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 24, 16, 6, and 18, and SEQ ID NOs: 27, 11, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NOs: 11, 27, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, as well as SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 22, 6, 20, and 28, as well as SEQ ID NOs: 23, 7, 21, and 29, SEQ ID NOs: 22, 20, 6, and 28, as well as SEQ ID NOs: 7, 21, 23, and 29, SEQ ID NOs: 26, 10, 20, and 28, as well as SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26, and 10, or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29, and 11. In some embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227. In some embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising, or consisting of, the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223.and one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or any one of SEQ ID NOs: 72 and 73, respectively. fusion polypeptides, SEQ ID NOs: 74 and 75, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; or fusion polypeptides, SEQ ID NOs: 76 and 77, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 78 and 79; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively. fusion polypeptides comprising SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 82 and 83, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;fusion polypeptides which are 96%, 97%, 98% or 99% identical, SEQ ID NOs: 84 and 85, or fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively, SEQ ID NOs: 86 and 87, or fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% identical to any one of SEQ ID NOs: 86 and 87, respectively; Fusion polypeptides that are 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 86, or any one of SEQ ID NOs: 82 and 86, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 88, or any one of SEQ ID NOs: 82 and 88, respectively; fusion polypeptides, SEQ ID NOs: 83 and 87, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; SEQ ID NOs: 88 and 87; or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. fusion polypeptides which are SEQ ID NOs: 84 and 88, or fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;fusion polypeptides that are 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; fusion polypeptides that are 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; 98 and 99, or any one of SEQ ID NOs: 98 and 99, respectively; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 100 and 101, or any one of SEQ ID NOs: 100 and 101, respectively.97%, 98%, or 99% identical fusion polypeptides. In some embodiments, the vector comprises one or more polynucleotides encoding, in N-terminal to C-terminal order, the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively. , SEQ ID NOs: 71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; SEQ ID NOs: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 73 and 72, or any one of SEQ ID NOs: 73 and 72, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 74 and 75, or any one of SEQ ID NOs: 74 and 75, respectively; fusion polypeptides that are 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 75 and 74, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively;fusion polypeptides that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 77 and 76, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to one of SEQ ID NOs: 79 and 78, respectively; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively; 80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; SEQ ID NOs: 81 and 80, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 81 and 80, respectively; 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,fusion polypeptides that are 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; fusion polypeptides that are 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; fusion polypeptides that are 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 86 and 87, or to any one of SEQ ID NOs: 86 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 87 and 86, or to any one of SEQ ID NOs: 87 and 86, respectively; fusion polypeptides that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 88 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 85 and 82, or any one of SEQ ID NOs: 85 and 82, respectively; SEQ ID NOs: 82 and 86, or any one of SEQ ID NOs: 82 and 86, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% identical to any one of SEQ ID NOs: 82 and 88, respectively; Fusion polypeptides that are 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 88 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 87 and 83, or to any one of SEQ ID NOs: 87 and 83, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 85 and 87, or to any one of SEQ ID NOs: 85 and 87, respectively;a fusion polypeptide that is 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 87 and 85, or at least 80% to any one of SEQ ID NOs: 87 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively. fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; fusion polypeptides which are 98% or 99% identical, SEQ ID NOs: 89 and 85, or fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively, SEQ ID NOs: 85 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% to any one of SEQ ID NOs: 85 and 101, respectively;fusion polypeptides that are 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 101 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; 91 and 90, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively; SEQ ID NOs: 92 and 93, or any one of SEQ ID NOs: 92 and 93, fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 93 and 92, respectively; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively;98% or 99% identical, SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively, SEQ ID NOs: 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, to any one of SEQ ID NOs: 97 and 96, respectively; 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; fusion polypeptides that are 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 95 and 97, or any one of SEQ ID NOs: 95 and 97, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 97 and 95, or any one of SEQ ID NOs: 97 and 95, respectively; fusion polypeptides SEQ ID NOs: 220 and 221 that are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or fusion polypeptides SEQ ID NOs: 221 and 220 that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively; SEQ ID NOs: 98 and 100; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively. fusion polypeptides, SEQ ID NOs: 100 and 98, or fusion polypeptides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively; fusion polypeptides, SEQ ID NOs: 99 and 101, or fusion polypeptides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 99 and 98, or to any one of SEQ ID NOs: 99 and 98, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 100 and 101, or to any one of SEQ ID NOs: 100 and 101, respectively;A fusion polypeptide that is 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 101 and 100, or any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively.comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 88 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively.In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively.In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively.In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively.In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the vector comprises one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively.In some embodiments, the vector comprises a polynucleotide encoding a composite fusion polypeptide comprising, or consisting of, the amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227. In some embodiments, the vector encodes a composite fusion polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223. In some embodiments, the first and second fusion polypeptides do not include any polypeptide segment corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or a fragment or subsequence thereof, where the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, the first and second fusion polypeptides do not comprise a polypeptide segment having an amino acid sequence of SEQ ID NOs: 35-47, or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or a fragment or subsequence thereof. In some embodiments, the vector comprises a polynucleotide comprising or consisting of the nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the vector comprises the nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226;In some embodiments, the polynucleotide comprises a first polynucleotide and a second polynucleotide: SEQ ID NOs: 130 and 132, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; Polynucleotides SEQ ID NOs: 131 and 133, which are 5%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 131 and 133, or polynucleotides SEQ ID NOs: 131 and 135, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 131 and 133, respectively. a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to one of SEQ ID NOs: 132 and 136, respectively; or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 132 and 136, respectively. leotide, SEQ ID NOs: 133 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively; SEQ ID NOs: 133 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% identical to any one of SEQ ID NOs: 133 and 137, respectively;Polynucleotides that are 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 134 and 136, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, respectively, SEQ ID NOs: 135 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively. Polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 138 and 141, or to any one of SEQ ID NOs: 138 and 141, respectively; SEQ ID NOs: 138 and 144, or to any one of SEQ ID NOs: 138 and 144, respectively. polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively; and 145, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; SEQ ID NOs: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to any one of SEQ ID NOs: 140 and 146, respectively;Polynucleotides that are 98% or 99% identical, SEQ ID NOs: 142 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively, SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. Polynucleotides that are 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively; SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 150 and 155, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively. 3, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; SEQ ID NOs: 151 and 156; or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to any one of SEQ ID NOs: 151 and 156, respectively;Polynucleotides that are 98% or 99% identical, SEQ ID NOs: 152 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively, SEQ ID NOs: 153 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively. Polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 154 and 157, or to any one of SEQ ID NOs: 154 and 157, respectively; SEQ ID NOs: 155 and 158, or to any one of SEQ ID NOs: 155 and 158, respectively. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 156 and 159, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. 1, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; SEQ ID NOs: 162 and 163; or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to any one of SEQ ID NOs: 162 and 163, respectively;Polynucleotides SEQ ID NOs: 164 and 165, which are 98% or 99% identical, or polynucleotides SEQ ID NOs: 166 and 167, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively; are polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; SEQ ID NOs: 210 and 211; or are polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 210 and 211, respectively. or 99% identical to SEQ ID NOs:212 and 213, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:212 and 213, respectively, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:214 and 215, respectively. Polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 216 and 217, or to any one of SEQ ID NOs: 216 and 217, respectively; polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively; 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 218 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively; or SEQ ID NOs: 225 and 226,or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide that comprises SEQ ID NO: 130 or SEQ ID NO: 131, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to SEQ ID NO: 130 or SEQ ID NO: 131, respectively. , 98% or 99% identical to SEQ ID NO:134 or SEQ ID NO:135, and (b) a second polynucleotide comprising SEQ ID NO:134 or SEQ ID NO:135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:134 or SEQ ID NO:135. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide that comprises SEQ ID NO:132 or SEQ ID NO:133, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to SEQ ID NO:132 or SEQ ID NO:133, respectively; , 98%, or 99% identical to SEQ ID NO: 139, and (b) a second polynucleotide comprising SEQ ID NO: 136 or SEQ ID NO: 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 136 or SEQ ID NO: 137. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 139, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 99% identical to SEQ ID NO: 139, respectively.and (b) a second polynucleotide comprising SEQ ID NO: 145 or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 145. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 142, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 142, respectively; and (b) a second polynucleotide comprising SEQ ID NO: 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 148. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 140, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 140, respectively; and (b) a second polynucleotide comprising SEQ ID NO: 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 146. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide that comprises SEQ ID NO: 143, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, respectively, identical to SEQ ID NO: 143;93%, 94%, 95%, 96%, 97%, 98% or 99% identical, and (b) a second polynucleotide comprising SEQ ID NO: 149 or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 149. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 150, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 150, respectively; and (b) a second polynucleotide comprising SEQ ID NO: 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 152. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 151, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 151, respectively; and (b) a second polynucleotide comprising SEQ ID NO: 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 153. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide that comprises SEQ ID NO: 154, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, or identical to SEQ ID NO: 154, respectively;97%, 98% or 99% identical, and (b) a second polynucleotide comprising SEQ ID NO: 157 or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 157. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 155, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 155, respectively; and (b) a second polynucleotide comprising SEQ ID NO: 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 158. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 156, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 156, respectively; and (b) a second polynucleotide comprising SEQ ID NO: 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 159. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide that comprises SEQ ID NO: 160, or that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 98% identical to SEQ ID NO: 160, respectively;98% or 99% identical, and (b) a second polynucleotide comprising SEQ ID NO: 161 or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161; In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 162, respectively, and (b) a second polynucleotide comprising SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 163. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 164, respectively; and (b) a second polynucleotide comprising SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 165. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 166, respectively; and (b) a second polynucleotide comprising SEQ ID NO: 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 167.In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO:210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:210, and (b) a second polynucleotide comprising SEQ ID NO:211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:211. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO:212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:212, and (b) a second polynucleotide comprising SEQ ID NO:213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:213. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO:214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:214, and (b) a second polynucleotide comprising SEQ ID NO:215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:215.In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO:216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:216, and (b) a second polynucleotide comprising SEQ ID NO:217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:217. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO:218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:218, and (b) a second polynucleotide comprising SEQ ID NO:219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:219. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO:218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:218, and (b) a second polynucleotide comprising SEQ ID NO:226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:226.In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO:225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:225, and (b) a second polynucleotide that comprises SEQ ID NO:226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:226. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are in a single open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is in a first open reading frame and the second polynucleotide encoding the second fusion polypeptide is in a second open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are in a single expression cassette. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is in a first expression cassette and the second polynucleotide encoding the second fusion polypeptide is in a second expression cassette. In some embodiments, the vector is a plasmid vector, a bacterial vector, or a viral vector. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is a DNA virus or an RNA virus. In some embodiments, the viral vector is replication-deficient, replication-defective, replication-attenuated, or replication-competent.In some embodiments, the viral vector is derived from a virus selected from adenovirus, adeno-associated virus, arenavirus, alphavirus, poxvirus, cytomegalovirus, rhabdovirus, vesicular stomatitis virus, flavivirus, Maraba virus, and vaccinia virus. In some embodiments, the viral vector is derived from a virus belonging to a taxonomic family selected from Adenoviridae, Arenaviridae, Herpesviridae (e.g., cytomegalovirus), Poxviridae (e.g., vaccinia virus, e.g., modified vaccinia Ankara (MVA)), Flaviviridae (e.g., yellow fever virus), Rhabdoviridae (e.g., vesiculovirus, e.g., Maraba vesiculovirus), or Togaviridae (e.g., alphavirus, e.g., Venezuelan equine encephalitis virus). In some embodiments, the viral vector is an arenavirus vector selected from lymphocytic choriomeningitis mammarenavirus (LCMV), Kali mammarenavirus (also known as Pichindemammarenavirus or Pichin de arenavirus), Guanarito virus (GTOV), Junin virus (JUNV), Lassa virus (LASV), Lujo virus (LUJV), Makupo virus (MACV), Sabia virus (SABV), and Whitewater Arroyo virus (WWAV). In some embodiments, the viral vector is an arenavirus vector selected from lymphocytic choriomeningitis mammarenavirus (LCMV) or Kali mammarenavirus (also known as Pichindemammarenavirus or Pichin de arenavirus). In some embodiments, the arenavirus vector comprises a two-segmented genome. In some embodiments, the arenavirus vector comprises a three-segmented genome. In some embodiments, the viral vector is a human adenovirus or a simian adenovirus (e.g., a chimpanzee adenovirus, a gorilla adenovirus, or a rhesus adenovirus).In some embodiments, the viral vector is selected from the group consisting of adenovirus serotype 5 (Ad5), adenovirus serotype 26 (Ad26), adenovirus serotype 34 (Ad34), adenovirus serotype 35 (Ad35), adenovirus serotype 48 (Ad48), chimpanzee adenovirus (e.g., ChAd3 (AdC3), ChAd5 (AdC5), ChAd6 (AdC6), ChAd7 (AdC7), ChAd8 (AdC8), ChAd9 (Ad C9), ChAd10(AdC10), ChAd11(AdC11), ChAd17(AdC17), ChAd16(AdC16), ChAd19(AdC19), ChAd20(AdC20), ChAd22(AdC22 ), ChAd24(AdC24), ChAdY25, ChAd26(AdC26), ChAd28(AdC28), ChAd30(AdC30), ChAd31(AdC31), ChAd37(AdC37), ChAd38. (AdC38), ChAd43(AdC43), ChAd44(AdC44), ChAd55(AdC55), ChAd63(AdC63), ChAdV63, ChAd68(AdC68), ChAd73(A dC73), ChAd82(AdC82), ChAd83(AdC83), ChAd143(AdC143), ChAd144(AdC144), ChAd145(AdC145), ChAd147(AdC1 47), gorilla adenovirus (e.g., GC44, GC45, GC46), and rhesus adenovirus (e.g., RhAd51, RhAd52, RhAd53, RhAd54, RhAd55, RhAd56, RhAd57, RhAd58, RhAd59, RhAd60, RhAd61, RhAd62, RhAd63, RhAd64, RhAd65, RhAd66).

[0013] Further provided are host cells comprising one or more polynucleotides, one or more expression cassettes, or one or more vectors described herein. In some embodiments, the one or more polynucleotides are not integrated into the host cell genome, e.g., are episomal. In some embodiments, the one or more polynucleotides are integrated into the host cell genome. In some embodiments, the host cell is a mammalian cell, e.g., a human cell. In various embodiments, the host cell can be in vitro or in vivo.

[0014] Immunogenic compositions are also provided. In various embodiments, the immunogenic compositions comprise one or more fusion polypeptides or multiple fusion polypeptides, one or more polynucleotides, or one or more vectors described herein, and a pharmaceutically acceptable carrier. In some embodiments, the immunogenic compositions comprise two or more of the fusion polypeptides or multiple fusion polypeptides, two or more polynucleotides, or two or more vectors described herein. In some embodiments, the one or more polynucleotides are DNA, cDNA, mRNA, or self-replicating RNA. In some embodiments, the immunogenic composition comprises one or more vectors comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, or the first and second fusion polypeptides, wherein the first and second polypeptides comprise, in N-terminal to C-terminal order, the following polypeptide segments, optionally linked or connected by one or more linkers: SEQ ID NOs: 6, 4, 16, and 26, and SEQ ID NOs: 7, 5, 27, and 17; SEQ ID NOs: 12, 24, 8, and 10, and SEQ ID NOs: 9, 25, 13, and 11; SEQ ID NOs: 14, 22, 18, 24, and 20, and SEQ ID NOs: 15, 25, 19, 23, and 21; SEQ ID NOs: 26, 16, 4, and 6, and SEQ ID NOs: 7, 27, 5, and 17; SEQ ID NOs: 8, 24, 12, and 10, and SEQ ID NOs: 13, 25, 9, and 11; SEQ ID NOs: 22, 24, 14, 18, and 20, and SEQ ID NOs: 25, 23, 15, 21, and 19, SEQ ID NOs: 20, 6, 4, 18, 16, and 26, and SEQ ID NOs: 7, 19, 5, 21, 27, and 17, SEQ ID NOs: 8, 24, 14, 12, 22, and 10, and SEQ ID NOs: 9, 13, 25, 23, 15, and 11, SEQ ID NOs: 18, 26, 20, 4, 6, and 16, and SEQ ID NOs: 7, 21, 17, 5, 27, and 19, SEQ ID NO: 22, 24, 12, 14, 8, and 10, and SEQ ID NOs: 15, 25, 9, 23, 13, and 11, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 7, 21, 5, 25, 33, and 19, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10,SEQ ID NOs: 8, 30, 14, 12, 26, and 10, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 6, 20, 4, 24, 32, and 18, and SEQ ID NOs: 8, 12, 30, 26, 14, and 10, SEQ ID NOs: 7, 21, 5, 25, 33, and 19, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 20, 32, 24, 4, 6, and 18, and SEQ ID NOs: 26, 30, 12, 14, 8, and 10, SEQ ID NOs: 7, 25, 19, 5, 33, and 21, and SEQ ID NOs: 15, 31, 9, 27, 13, and 11, and SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 20, 10, and 28, and SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 10, 20, and 28, and SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: Nos. 7, 25, 17, and 19, SEQ ID NOs: 7, 19, 17, and 25, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 24, 16, 6, and 18, and SEQ ID NOs: 27, 11, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NOs: 11, 27, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: SEQ ID NOs: 22, 6, 20, and 28, and SEQ ID NOs: 23, 7, 21, and 29; SEQ ID NOs: 22, 20, 6, and 28, and SEQ ID NOs: 7, 21, 23, and 29; SEQ ID NOs: 26, 10, 20, and 28, and SEQ ID NOs: 21, 27, 11, and 29; SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26, and 10, or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29, and 11. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides or vectors comprising one or more polynucleotides encoding one or more fusion polypeptides comprising, or consisting of, the amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227.The immunogenic compositions include one or more fusion polypeptides, or vectors comprising one or more polynucleotides encoding one or more fusion polypeptides comprising, or consisting of, the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223. In some embodiments, the immunogenic composition comprises one or more polynucleotides, or one or more vectors or one or more lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73; or any one of SEQ ID NOs: 72 and 73 and its fusion polypeptides. fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; fusion polypeptides that are 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% to any one of SEQ ID NOs: 76 and 77, respectively;fusion polypeptides that are 98% or 99% identical, SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively, SEQ ID NOs: 80 and 81, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 83, or to any one of SEQ ID NOs: 82 and 83, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 86 and 87, or any one of SEQ ID NOs: 86 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 88 and 89, or any one of SEQ ID NOs: 88 and 89, respectively; fusion polypeptides, SEQ ID NOs: 82 and 85, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; SEQ ID NOs: 82 and 88; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. fusion polypeptides which are SEQ ID NOs: 83 and 87, or fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87, or fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; fusion polypeptides that are 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 85 and 89, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;fusion polypeptides that are 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 92 and 93, or to any one of SEQ ID NOs: 92 and 93, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 94 and 95, or to any one of SEQ ID NOs: 94 and 95, respectively; 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, or a fusion polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to one of SEQ ID NOs: 95 and 97, respectively; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; 20 and 221, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;Fusion polypeptides that are 98% or 99% identical, SEQ ID NOs: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 100 and 101, or any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the immunogenic composition comprises one or more polynucleotides, or one or more vectors or one or more lipoplexes (e.g., LNPs), comprising one or more polynucleotides encoding the following first and second fusion polypeptides, in N-terminal to C-terminal order, optionally linked or connected by one or more linkers: SEQ ID NOs: 70 and 71, or a sequence identical to any one of SEQ ID NOs: 70 and 71, respectively, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 1109%, 1111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 1510%, 1520%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 16 fusion polypeptides that are 1%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 71 and 70, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% identical to any one of SEQ ID NOs: 72 and 73, respectively;Fusion polypeptides that are 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 73 and 72, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 75 and 74, or to any one of SEQ ID NOs: 75 and 74, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; fusion polypeptides, SEQ ID NOs: 77 and 76, that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively; or fusion polypeptides, SEQ ID NOs: 78 and 79, or SEQ ID NOs: 78 and 79, that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively. 79 and 78, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 79 and 78, respectively;fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 80 and 81, or any one of SEQ ID NOs: 80 and 81, respectively; 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; fusion polypeptides that are 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 86 and 87, or any one of SEQ ID NOs: 86 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 87 and 86, or any one of SEQ ID NOs: 87 and 86, respectively;fusion polypeptides that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to one of SEQ ID NOs: 82 and 85, respectively; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively; 85 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively; SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; fusion polypeptides SEQ ID NOs: 86 and 82, or fusion polypeptides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 82, respectively; fusion polypeptides SEQ ID NOs: 82 and 88, or fusion polypeptides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;fusion polypeptides that are 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92, fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 83 and 87, or any one of SEQ ID NOs: 83 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 87 and 83, or any one of SEQ ID NOs: 87 and 83, respectively; , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively; fusion polypeptides that are 1%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 88 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively; 8, SEQ ID NOs: 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively;SEQ ID NOs: 88 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; SEQ ID NOs: 85 and 89, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 91 and 90, or to any one of SEQ ID NOs: 91 and 90, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 92 and 93, or to any one of SEQ ID NOs: 92 and 93, respectively;fusion polypeptides, SEQ ID NOs: 93 and 92, which are 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; or fusion polypeptides, SEQ ID NOs: 94 and 95, or SEQ ID NOs: 94 and 95, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively; 95 and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 94, respectively; 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 97 and 96, or any one of SEQ ID NOs: 97 and 96, respectively; 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively;Fusion polypeptides that are 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 95, respectively. fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 220 and 221, or to any one of SEQ ID NOs: 220 and 221, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 221 and 220, or to any one of SEQ ID NOs: 221 and 220 and fusion polypeptides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 98 and 100, respectively; or fusion polypeptides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 99% identical to any one of SEQ ID NOs: 99 and 101,fusion polypeptides, SEQ ID NOs: 101 and 99, which are 98% or 99% identical; or fusion polypeptides, SEQ ID NOs: 98 and 99, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 99, respectively; 98 and 99, respectively, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, or at least 80%, 81%, 82%, 83%, 84%, or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively, fusion polypeptides that are 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 100 and 101, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% identical to any one of SEQ ID NOs: 100 and 101, respectively; , 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 101 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides, first and second viral vectors, or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 83, or a first fusion polypeptide and a second fusion polypeptide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, or 93% homologous to any one of SEQ ID NOs: 82 and 83, respectively;(b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical; (b) a first fusion polypeptide comprising SEQ ID NOs: 86 and 87; and a second fusion polypeptide, or a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is:In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is:In some embodiments, the immunogenic composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively.In some embodiments, the immunogenic composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively.In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., an LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is:In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is: In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively.In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: SEQ ID NOs: 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In some embodiments, the composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) first and second fusion polypeptides comprising SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the immunogenic compositions are optionally linked or connected by one or more linkers. and a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or one or more polynucleotides encoding fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising a nucleotide; (b) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively.In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a first fusion polypeptide and a second fusion polypeptide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., an LNP) comprising one or more polynucleotides encoding identical fusion polypeptides; (c) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or a second polynucleotide or a second viral vector or a second lipoplex (e.g., an LNP) comprising one or more polynucleotides encoding fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively.In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively. (b) a first polynucleotide or a first viral vector or a first lipoplex (e.g., an LNP) comprising one or more polynucleotides encoding a fusion polypeptide which is: In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally linked or connected by one or more linkers, comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively.In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally linked or connected by one or more linkers, comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally linked or connected by one or more linkers, comprising SEQ ID NOs: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally linked or connected by one or more linkers, comprising SEQ ID NOs: 87 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively.In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally linked or connected by one or more linkers, comprising SEQ ID NOs: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively. In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally linked or connected by one or more linkers, comprising SEQ ID NOs: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally linked or connected by one or more linkers, comprising SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively.In some embodiments, the immunogenic composition comprises a viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, optionally linked or connected by one or more linkers, comprising SEQ ID NOs: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., a first polynucleotide encoding a first polypeptide comprising SEQ ID NO:200, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:200. and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide encoding a polypeptide comprising SEQ ID NO:201, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:201.In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., a first polynucleotide encoding a first polypeptide comprising SEQ ID NO:202, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:202. and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide encoding a polypeptide comprising SEQ ID NO:203, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:203. In some embodiments, the immunogenic composition comprises a first viral vector or lipoprotein comprising a first polynucleotide encoding a polypeptide comprising SEQ ID NO:203, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:203. a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide encoding a polypeptide comprising SEQ ID NO:204, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:204. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide encoding a polypeptide comprising SEQ ID NO: 105, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 105. and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide encoding a polypeptide comprising SEQ ID NO:107, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:107. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., a first polynucleotide encoding a first polypeptide comprising SEQ ID NO:206, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:206. and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide encoding a polypeptide comprising SEQ ID NO:207, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:207. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide encoding a polypeptide comprising SEQ ID NO:208, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:208; and a secondand a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide encoding a polypeptide comprising SEQ ID NO:209 or SEQ ID NO:227, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:209 or SEQ ID NO:227. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide encoding a polypeptide comprising SEQ ID NO:222, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:222; and a second polynucleotide encoding a polypeptide comprising SEQ ID NO:222. and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide encoding a polypeptide comprising SEQ ID NO:209 or SEQ ID NO:227, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:209 or SEQ ID NO:227. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex comprising a first polynucleotide encoding a polypeptide comprising SEQ ID NO:222, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:222. (e.g., LNP) and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide encoding a polypeptide comprising SEQ ID NO:223, or a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:223;In some embodiments, the immunogenic composition comprises a polynucleotide comprising or consisting of the nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the immunogenic composition comprises a polynucleotide comprising, or consisting of, the nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226. In some embodiments, the immunogenic composition comprises one or more vectors comprising the following first and second polynucleotides, or the following first and second polynucleotides: SEQ ID NOs: 130 and 132, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130 and 132, respectively; and 134, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 130 and 134, respectively; SEQ ID NOs: 131 and 133, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively;Polynucleotides that are 96%, 97%, 98% or 99% identical to SEQ ID NOs: 131 and 135, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; SEQ ID NOs: 132 and 136; or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87% identical to any one of SEQ ID NOs: 132 and 136, respectively. , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 133 and 135, or to any one of SEQ ID NOs: 133 and 135, respectively; or to any one of SEQ ID NOs: 133 and 137, or to any one of SEQ ID NOs: 133 and 137, respectively. polynucleotides SEQ ID NOs:134 and 136 which are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:134 and 136, respectively; or polynucleotides SEQ ID NOs:135 and 136 which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:134 and 136, respectively. 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; SEQ ID NOs: 138 and 141, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to any one of SEQ ID NOs: 138 and 141, respectively;Polynucleotides that are 98% or 99% identical, SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively, SEQ ID NOs: 139 and 142, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively. Polynucleotides that are 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 139 and 145, or to any one of SEQ ID NOs: 139 and 145, respectively; polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 142 and 148, or polynucleotides SEQ ID NOs: 143 and 144 that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. 9, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; SEQ ID NOs: 145 and 148; or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively;Polynucleotides which are 98% or 99% identical, SEQ ID NOs: 150 and 152, or polynucleotides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; SEQ ID NOs: 150 and 155, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 155, respectively; SEQ ID NOs: 151 and 153, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively; 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 156, or to any one of SEQ ID NOs: 151 and 156, respectively; SEQ ID NOs: 152 and 158, or to any one of SEQ ID NOs: 152 and 158, respectively; polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 153 and 159, or to any one of SEQ ID NOs: 153 and 159, respectively; polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 154 and 157, or to any one of SEQ ID NOs: 154 and 157, respectively; polynucleotides SEQ ID NOs: 155 and 158 which are 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or polynucleotides SEQ ID NOs: 156 and 159 which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively;or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively; SEQ ID NOs: 160 and 161; or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively. Polynucleotides SEQ ID NOs: 162 and 163, or polynucleotides SEQ ID NOs: 164 and 165, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively; , 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 166 and 167, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; SEQ ID NOs: 210 and 211, or polynucleotides that are at least 80% identical to any one of SEQ ID NOs: 210 and 211, respectively; polynucleotides SEQ ID NOs:212 and 213, which are 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or polynucleotides SEQ ID NOs:214 and 215, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs:212 and 213, respectively;or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively; SEQ ID NOs: 216 and 217; or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively. a polynucleotide that is 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 218 and 219, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 219, respectively; 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 218 and 226, respectively. 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 225 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 225 and 226, or any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) a first vector or first lipoplex (e.g., LNPs) comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively;(b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 98% homologous to any one of SEQ ID NOs: 139 and 145, respectively; (b) a first vector or a first lipoplex (e.g., LNP) comprising a polynucleotide that is 98% or 99% identical to SEQ ID NOs: 142 and 148, and (c) a second vector or a second lipoplex (e.g., LNP) comprising first and second polynucleotides that comprise SEQ ID NOs: 142 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) a first vector or first lipoplex (e.g., LNPs) comprising first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively;(b) a second vector or second lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, respectively, to any one of SEQ ID NOs: 143 and 149. In some embodiments, the first and second viral vectors of such immunogenic compositions are lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively. (b) a first vector or a first lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, and (b) a second vector or a second lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the first and second viral vectors of such immunogenic compositions are Kalimanmarenavirus (also known as Pichindemanmarenavirus or Pichindearenavirus) viral vectors. In some embodiments, the immunogenic composition comprises a first polynucleotide and a second polynucleotide:the first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising: (a) first and second polynucleotides comprising SEQ ID NOs: 151 and 153, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% identical to any one of SEQ ID NOs: 151 and 153, respectively; (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 160, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, of SEQ ID NO: 160. (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide identical to SEQ ID NO: 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161, respectively.In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 162, or a polynucleotide having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology with SEQ ID NO: 162, respectively. (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide identical to SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, of SEQ ID NO: 164. (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide identical to SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 165, respectively.In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, respectively, of SEQ ID NO: 166. (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide identical to SEQ ID NO: 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167, respectively. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 210, or a polynucleotide of SEQ ID NO: 210 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide identical to SEQ ID NO: 211, and (c) a second viral vector or a second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 211 or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211.In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 212, or a polynucleotide of SEQ ID NO: 212 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide identical to SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 214, or a polynucleotide of SEQ ID NO: 214 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide identical to SEQ ID NO: 215, and (c) a second viral vector or a second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 215 or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215.In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 216, or a polynucleotide of SEQ ID NO: 216 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide identical to SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 218, or a polynucleotide of SEQ ID NO: 218 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide identical to SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219.In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 218, or a polynucleotide of SEQ ID NO: 218 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide identical to SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the immunogenic composition comprises first and second polynucleotides or first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 225, or a polynucleotide of SEQ ID NO: 225 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (b) a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide identical to SEQ ID NO: 226, (c) a second viral vector or a second lipoplex (e.g., LNP) comprising a polynucleotide of SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 226. In some embodiments, the immunogenic composition comprises a vector or lipoplex comprising a composite fusion polypeptide and a polynucleotide encoding the composite fusion polypeptide. and a nucleic acid sequence (e.g., LNP), and the composite fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 105 to 112, 200 to 209, 222 to 223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 105 to 112, 200 to 209, 222 to 223, and 227. In some embodiments, an immunogenic composition comprises a composite fusion polypeptide and a vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding the composite fusion polypeptide, wherein the composite fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223. In some embodiments, one or more fusion polypeptides do not include any polypeptide segment corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or a fragment or subsequence thereof, where the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, one or more fusion polypeptides do not comprise a polypeptide segment having an amino acid sequence of SEQ ID NOs: 35-47, or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or a fragment or subsequence thereof.In various embodiments of the immunogenic composition, the first and second viral vectors can be lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors, Kali mammarenavirus (also known as Pichinde mammarenavirus or Pichinde arenavirus) viral vectors, or adenoviral vectors, e.g., chimpanzee adenoviral vectors (ChAds). In some embodiments, the immunogenic composition comprises a single vector comprising one or more polynucleotides encoding the first and second fusion polypeptides. In some embodiments, the immunogenic composition further comprises one or more of an adjuvant, a detergent, a micelle-forming agent, and an oil. In some embodiments, the immunogenic composition is formulated for administration via a route selected from intravenous, intramuscular, intradermal, subcutaneous, intranodal, and intramucosal (e.g., buccal, intranasal, rectal, intravaginal) administration. In some embodiments, the immunogenic composition is formulated as a liquid, suspension, or emulsion. In some embodiments, the immunogenic composition is lyophilized.

[0015] Further provided are kits comprising one or more unit doses of one or more fusion polypeptides, one or more multiple fusion polypeptides, one or more polynucleotides, one or more vectors, or one or more immunogenic compositions described herein. In some embodiments, the kit comprises two or more of the fusion polypeptides, two or more multiple fusion polypeptides, two or more polynucleotides, two or more vectors, or two or more immunogenic compositions described herein. In some embodiments, the one or more unit doses are in a single container. In some embodiments, the one or more unit doses are in two or more separate containers. In some embodiments, the kit comprises one or more containers selected from vials, ampoules, and pre-filled syringes. In some embodiments, the kit comprises one or more containers containing one or more fusion polypeptides, one or more polynucleotides, or one or more vectors in aqueous solution. In some embodiments, the one or more unit doses are the same. In some embodiments, the one or more unit doses are different. In some embodiments, the kit comprises one or more unit doses of one or more viral vectors, wherein the unit doses are about 10 3 ~about 10 12 Viral focus-forming units (FFU) or plaque-forming units (PFU) or infectious units (IU) or viral particles (vp), for example, about 10 4 ~about 10 7 Viral FFU or PFU or IU or vp, for example, about 10 3 ~about 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 or 10 15In some embodiments, the kit includes one or more vectors comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, or a first and second fusion polypeptide, wherein the first and second polypeptides comprise, in N-terminal to C-terminal order, the following polypeptide segments, optionally linked or connected by one or more linkers: SEQ ID NOs: 6, 4, 16, and 26, and SEQ ID NOs: 7, 5, 27, and 17; SEQ ID NOs: 12, 24, 8, and 10; and SEQ ID NOs: 9, 25, 13, and 11; 14, 22, 18, 24, and 20, and SEQ ID NOs: 15, 25, 19, 23, and 21, SEQ ID NOs: 26, 16, 4, and 6, and SEQ ID NOs: 7, 27, 5, and 17, SEQ ID NOs: 8, 24, 12, and 10, and SEQ ID NOs: 13, 25, 9, and 11, SEQ ID NOs: 22, 24, 14, 18, and 20, and SEQ ID NOs: 25, 23, 15, 21, and 19, SEQ ID NOs: 20, 6, 4, 18, 16, and 26, and SEQ ID NOs: 7, 19, 5, 21, 27, and 17, SEQ ID NOs: 8, 24, 14, 12, 22, and 10, and SEQ ID NOs: 9, 13, 25, 23, 15, and 11, SEQ ID NOs: 18, 26, 20, 4, 6, and 16, and SEQ ID NOs: 7, 21, 17, 5, 27, and 19, SEQ ID NOs: 22, 24, 12, 14, 8, and 10, and SEQ ID NOs: 15, 25, 9, 23, 13, and 11, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 7, 21, 5, 25, 33, and 19, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 2 6, and 10, SEQ ID NOs: 8, 30, 14, 12, 26, and 10, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 6, 20, 4, 24, 32, and 18, and SEQ ID NOs: 8, 12, 30, 26, 14, and 10, SEQ ID NOs: 7, 21, 5, 25, 33, and 19, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 20, 32, 24, 4, 6, and 18, and SEQ ID NOs: 26, 30, 12, 14, 8, and 10, SEQ ID NOs: 7, 25, 19, 5, 33, and 21, and SEQ ID NOs: 15, 31, 9, 27, 13,and 11, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 20, 10, and 28, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 10, 20, and 28, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 7, 25, 17, and 19, SEQ ID NOs: 7, 19, 17, and 25, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 24, 16, 6, and 18, and SEQ ID NOs: 27, 11, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NO: 11, 27, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 22, 6, 20, and 28, and SEQ ID NOs: 23, 7, 21, and 29, SEQ ID NOs: 22, 20, 6, and 28, and SEQ ID NOs: 7, 21, 23, and 29, SEQ ID NOs: 26, 10, 20, and 28, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26, and 10, or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29, and 11. In some embodiments, the kit comprises one or more vectors or one or more lipoplexes (LNPs) comprising one or more polynucleotides encoding one or more fusion polypeptides, the one or more fusion polypeptides comprising or consisting of the amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides, the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223;In some embodiments, the kit comprises one or more vectors or one or more lipoplexes (LNPs) comprising one or more polynucleotides encoding one or more fusion polypeptides, such as, or consisting of, the following: a first fusion polypeptide and a second fusion polypeptide, or one or more polynucleotides encoding the following first fusion polypeptide and a second fusion polypeptide, optionally linked or connected by one or more linkers: SEQ ID NOs: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% of any one of SEQ ID NOs: 70 and 71, respectively. fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, or SEQ ID NOs: 72 and 73, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, or SEQ ID NOs: 74 and 75, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; 9, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 78 and 79, respectively; SEQ ID NOs: 80 and 81; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95% identical to any one of SEQ ID NOs: 80 and 81, respectively;fusion polypeptides which are 96%, 97%, 98% or 99% identical, SEQ ID NOs: 82 and 83, or fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively, SEQ ID NOs: 84 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% to any one of SEQ ID NOs: 84 and 85, respectively; Fusion polypeptides that are 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 85, or any one of SEQ ID NOs: 82 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 86, or any one of SEQ ID NOs: 82 and 86, respectively; fusion polypeptides, SEQ ID NOs: 82 and 88, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; SEQ ID NOs: 85 and 87; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. , 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 88 and 87, or to any one of SEQ ID NOs: 88 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; fusion polypeptides that are 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 85 and 101, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively; fusion polypeptides, SEQ ID NOs: 92 and 93, which are 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; or fusion polypeptides, SEQ ID NOs: 94 and 95, or SEQ ID NOs: 94 and 95, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively; 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively;SEQ ID NOs: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; fusion polypeptides that are at least 7%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 99 and 101, or to any one of SEQ ID NOs: 99 and 101, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 98 and 99, or to any one of SEQ ID NOs: 98 and 99, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 100 and 101, or to any one of SEQ ID NOs: 100 and 101, respectively.one or more vectors, or one or more lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, in N-terminal to C-terminal order, optionally linked or connected by one or more linkers: SEQ ID NOs: 70 and 71, or a sequence encoding any one of SEQ ID NOs: 70 and 71 at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 1109%, 1111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151, 152, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161, 162, 163%, 164%, 165%, fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 71 and 70, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively; fusion polypeptides that are 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 73 and 72, or to any one of SEQ ID NOs: 73 and 72, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 74 and 75, or to any one of SEQ ID NOs: 74 and 75, respectively; fusion polypeptides, SEQ ID NOs: 75 and 74, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 75 and 74, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; SEQ ID NOs: 77 and 76; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively. fusion polypeptides, SEQ ID NOs: 78 and 79, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 79 and 78, or any one of SEQ ID NOs: 79 and 78, respectively; , 96%, 97%, 98% or 99% identical to SEQ ID NOs: 80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 80 and 81, respectively. fusion polypeptides that are 0%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; fusion polypeptides that are 0%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, or at least 80%, 81%, 82%, 83%, 84% identical to any one of SEQ ID NOs: 83 and 82, respectively;fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 84 and 85, or any one of SEQ ID NOs: 84 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 85 and 84, or any one of SEQ ID NOs: 85 and 84, respectively; fusion polypeptides, SEQ ID NOs: 86 and 87, which are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; or fusion polypeptides, SEQ ID NOs: 87 and 86, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; SEQ ID NOs: 88 and 89; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively. 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively; SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96% identical to any one of SEQ ID NOs: 82 and 85, respectively;97%, 98% or 99% identical to SEQ ID NOs: 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively; fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; fusion polypeptides that are 4%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 88, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; fusion polypeptides that are 4%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively; Fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 83 and 87, or to any one of SEQ ID NOs: 83 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 87 and 83, or to any one of SEQ ID NOs: 87 and 83, respectively. fusion polypeptides, SEQ ID NOs: 85 and 87, that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively; SEQ ID NOs: 88 and 87; or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively; fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively; fusion polypeptides which are 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 89 and 85, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 85, respectively; fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively;fusion polypeptides that are 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 101 and 85, or to any one of SEQ ID NOs: 101 and 85, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 90 and 91, or to any one of SEQ ID NOs: 90 and 91. fusion polypeptides, SEQ ID NOs: 91 and 90, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 91 and 90, respectively; or fusion polypeptides, SEQ ID NOs: 92 and 93, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 91 and 90, respectively. 3, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively, SEQ ID NOs: 93 and 92, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 93 and 92, respectively. fusion polypeptides that are identical, SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively;fusion polypeptides that are 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 97 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% to any one of SEQ ID NOs: 97 and 96, respectively; fusion polypeptides that are 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 94 and 96, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; fusion polypeptides that are 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; fusion polypeptides, SEQ ID NOs: 95 and 97, that are 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, or a fusion polypeptide, SEQ ID NOs: 97 and 95, or any of SEQ ID NOs: 97 and 95, that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, respectively, any one of SEQ ID NOs: 95 and 97; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to one of SEQ ID NOs: 220 and 221, respectively; or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively;SEQ ID NOs: 221 and 220, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 221 and 220, respectively; SEQ ID NOs: 98 and 100, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 98, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 101 and 99, or to any one of SEQ ID NOs: 101 and 99, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 98 and 99, or to any one of SEQ ID NOs: 98 and 99, respectively; fusion polypeptides SEQ ID NOs: 99 and 98 that are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or fusion polypeptides SEQ ID NOs: 100 and 101 that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 98, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 101 and 100, or SEQ ID NOs: 101 and 100, respectively. fusion polypeptides that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical. In some embodiments, the kit includes first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs) that include one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 83, or at least 80%, 81%, 82%, 83%, 84%, or 85% identical to any one of SEQ ID NOs: 82 and 83, respectively. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; (b) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 85, or a second fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding fusion polypeptides that are 7%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; (c) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 86 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively; a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively;and a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively. (b) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding identical fusion polypeptides; (b) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) one or more polynucleotides encoding first and second fusion polypeptides comprising SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;(b) a first viral vector or lipoplex (e.g., LNP); and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a first fusion polypeptide and a second fusion polypeptide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 88, respectively. (b) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding identical fusion polypeptides; (c) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 87, or a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively. In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) that include one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO:200, or a fusion polypeptide comprising at least 80%, 81%, 82%, 83%, or a polypeptide having ...(b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:201; and (c) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that comprises SEQ ID NO:201, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:201. In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO:202, or a fusion polypeptide comprising SEQ ID NO:202 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more of ... (b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203; and (c) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) that include one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO:204, or a fusion polypeptide comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, or a fusion polypeptide comprising SEQ ID NO:204;(b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 205; and (c) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that comprises SEQ ID NO: 205, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 205. In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO: 105 or 206, or a fusion polypeptide comprising at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more of SEQ ID NO: 105 or 206, respectively. (b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 107 or 207, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107 or 207, respectively. In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) that include one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO:208, or at least 80%, 81%, 82%, or both SEQ ID NO:208 and SEQ ID NO:208;(b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 209; or a fusion polypeptide comprising SEQ ID NO:227, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:209 or SEQ ID NO:227. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO:222, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:222. (b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO:209 or SEQ ID NO:227, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:209 or SEQ ID NO:227. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO:222, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:222;(b) a first viral vector or lipoplex (e.g., LNP); and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 223, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. In some embodiments, the kit includes first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNPs) comprising one or more polynucleotides encoding first and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87; (c) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a peptide or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; a third viral vector or lipoplex (e.g., a third viral vector or lipoplex) comprising one or more polynucleotides encoding the first fusion polypeptide and the second fusion polypeptide, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively;LNP), (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 85 and 89, respectively. In some embodiments, the kit includes first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNPs) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a first fusion polypeptide comprising SEQ ID NOs: 83 and 87; and a second fusion polypeptide, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. (c) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively;a third viral vector or lipoplex (e.g., LNP); (d) a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. In some embodiments, the kit includes first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNPs) comprising one or more polynucleotides encoding first and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; (b) a first viral vector or lipoplex (e.g., LNPs) comprising one or more polynucleotides encoding first and second fusion polypeptides comprising SEQ ID NOs: 82 and 86, respectively; one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively. (c) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or any one of SEQ ID NOs: 98 and 100, respectively;(d) a third viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is 98% or 99% identical to the first fusion polypeptide and the second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or a fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively. In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 90 and 91, or a first fusion polypeptide and a second fusion polypeptide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 90 and 91, respectively. (b) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding identical fusion polypeptides, and (c) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding first and second fusion polypeptides comprising SEQ ID NOs: 92 and 93, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers:LNPs): (a) one or more polynucleotides encoding the following first and second fusion polypeptides comprising SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively; (b) a first viral vector or lipoplex (e.g., LNP); and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides comprising SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a first fusion polypeptide and a second fusion polypeptide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively. (b) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is 9% identical to SEQ ID NOs: 95 and 97; and (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides comprising SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first and second fusion polypeptide comprising SEQ ID NOs: 94 and 95,or 95, respectively, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 94 and 95; (b) a first viral vector or lipoplex (e.g., LNP) comprising: A second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide and a second fusion polypeptide, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 96 and 97, respectively. In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a first fusion polypeptide and a second fusion polypeptide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively. In some embodiments, the kit comprises: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding identical fusion polypeptides; (b) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively.and first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or a first fusion polypeptide and a second fusion polypeptide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 1109%, 1111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160%, 161, 162, 163, 164, 16 (b) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively; a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide; (c) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or one or more polynucleotides encoding fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively. (d) a third viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or a fourth viral vector or lipoplex (e.g.,In some embodiments, the kit includes first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs) that include one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or a first fusion polypeptide and a second fusion polypeptide that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 1109%, 1111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 1510%, 1520%, 1530%, 1540%, 1550%, 1560%, 1570%, 1580%, 1590%, 1610%, 1620%, 96 and 97, or a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, (c) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively. (d) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 100 and 101, or one or more polynucleotides encoding fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively;A fourth viral vector or lipoplex (e.g., LNP). In various embodiments of the kit, the first and second viral vectors are lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors, Kali mammarenavirus (also known as Pichinde mammarenavirus or Pichinde arenavirus) viral vectors, or adenoviral vectors, such as chimpanzee adenoviral vectors (ChAds). In some embodiments, the kit comprises a polynucleotide comprising or consisting of the nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the kit comprises a polynucleotide comprising or consisting of the nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226. In some embodiments, the kit comprises the following first and second polynucleotides, one or more vectors or one or more lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: SEQ ID NOs: 130 and 132, or a polynucleotide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130 and 134 ... respectively;a polynucleotide that is 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 131 and 133, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 131 and 133, respectively; polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 131 and 135, or to any one of SEQ ID NOs: 131 and 135, respectively; polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 132 and 136, or to any one of SEQ ID NOs: 132 and 136, respectively; SEQ ID NOs: 133 and 135, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 135, respectively. and 137, or any one of SEQ ID NOs: 133 and 137, respectively, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 134 and 136, or any one of SEQ ID NOs: 134 and 136, respectively. polynucleotides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively; polynucleotides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 135 and 137, respectively;Polynucleotides that are 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 138 and 144, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 138 and 144, respectively; SEQ ID NOs: 139 and 142; or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 142, respectively. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 139 and 145, or to any one of SEQ ID NOs: 139 and 145, respectively; or to SEQ ID NOs: 140 and 146, or to SEQ ID NOs: 140 and 146, respectively. a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively; or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively. SEQ ID NOs: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; SEQ ID NOs: 145 and 148, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 145 and 148, respectively;Polynucleotides that are 96%, 97%, 98% or 99% identical to SEQ ID NOs: 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively, SEQ ID NOs: 150 and 155, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87% to any one of SEQ ID NOs: 150 and 155, respectively , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 151 and 153, or to any one of SEQ ID NOs: 151 and 153, respectively; SEQ ID NOs: 151 and 156, or to any one of SEQ ID NOs: 151 and 156, respectively. polynucleotides SEQ ID NOs: 152 and 158 which are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively; or polynucleotides SEQ ID NOs: 153 and 154 which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 152 and 158, respectively. 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 153 and 159, respectively; SEQ ID NOs: 154 and 157, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to any one of SEQ ID NOs: 154 and 157, respectively;Polynucleotides that are 98% or 99% identical, SEQ ID NOs: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively, SEQ ID NOs: 156 and 159, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. Polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 160 and 161, or to any one of SEQ ID NOs: 160 and 161, respectively; SEQ ID NOs: 162 and 163; or to any one of SEQ ID NOs: 162 and 163, respectively. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 164 and 165, or polynucleotides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 164 and 165, respectively. 7, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; SEQ ID NOs: 210 and 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to any one of SEQ ID NOs: 210 and 211, respectively;polynucleotides which are 98% or 99% identical, SEQ ID NOs: 212 and 213, or polynucleotides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 212 and 213, respectively; SEQ ID NOs: 214 and 215, or polynucleotides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 214 and 215, respectively; a polynucleotide that is 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 216 and 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 216 and 217, respectively; a polynucleotide, SEQ ID NO:218 and 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:218 and 219, respectively; a polynucleotide, SEQ ID NO:218 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO:218 and 226, respectively; 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 225 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NOs: 225 and 226, or any one of SEQ ID NOs: 225 and 226, respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs: 131 and 135;or any one of SEQ ID NOs: 131 and 135, respectively; (b) a first vector or lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 131 and 135, respectively; A second vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising sequence numbers 133 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively. In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively; (b) a first vector or lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either one of SEQ ID NOs: 139 and 145, respectively;In some embodiments, the kit comprises first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNPs) comprising first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 1109%, 1111, 1120, 1130, 1140, 1150, 1160, 1170, 1180, 1190, 1200, 1210, 1220, 1230, 1240, 1250, 1260, 1270, 1280, 1290, 1300, 1311, 1320, 1330, 1340, 1350, 1360, 1370, 1380, 1390, 1400, 1410, 1420, 1430, 1440, 1450, 1460, 1470, 1480, 1490, 1500, 1510, 1520, 1530, 1540, 1550, 1560, 1570, 1580, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; (b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 133 and 137, respectively; (c) a second viral vector or lipoplex (e.g., LNP) comprising the first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 139 and 145, respectively. a viral vector or lipoplex (e.g., LNP); (d) a fourth viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 142 and 148, respectively.In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 140 and 146, respectively; (b) a first vector or lipoplex (e.g., LNP) comprising a polynucleotide that is identical to SEQ ID NOs: 143 and 149, and (c) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 143 and 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively. In some embodiments, the first and second viral vectors are lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors.In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively; (b) a first vector or lipoplex (e.g., LNP), and (c) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively. In some embodiments, the first and second viral vectors are Kalimanmarenavirus (also known as Pichindemanmarenavirus or Pichindearenavirus) viral vectors.In some embodiments, the kit includes first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNPs) comprising first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs: 140 and 146, or having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 1109%, 1110, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146, 147%, 148%, 149%, 150%, 1510, 1520, 1530, 1540, 1550, 1560, 1570, 1580, 1590, 1591, 1592, 1593, 1594, 1595, 15 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; (b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 143 and 149, respectively; (c) a second viral vector or lipoplex (e.g., LNP) comprising the first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 150 and 152, respectively. P), (d) a fourth viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, respectively.In some embodiments, the kit includes first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs), each vector or lipoplex (e.g., LNPs) comprising first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs: 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 1109%, 1111, 1120, 1130, 1140, 1150, 1160, 1170, 1180, 1190, 1200, 1210, 1220, 1230, 1240, 1250, 1260, 1270, 1280, 1290, 1300, 1310, 1320, 1330, 1340, 1350, 1360, 1370, 1380, 1390, 1400, 1410, 1420, 1430, 1440, 1450, 1460, 1470, 1480, 1490, 1501, 1512, 1521, 1530, 1540, 1550, 1560, 1570, 1580, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; (b) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 155 and 158, respectively; (c) a second viral vector or lipoplex (e.g., LNP) comprising the first and second polynucleotides comprising SEQ ID NOs: 151 and 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 151 and 153, respectively. a viral vector or lipoplex (e.g., LNP), and (d) a fourth viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 156 and 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 156 and 159, respectively. In various embodiments, one or more of the first, second, third, and fourth vectors is an adenoviral vector.In some embodiments, the kit includes first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs: 160 and 161, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 160 and 161, respectively; (b) a first vector or lipoplex (e.g., LNP) comprising a polynucleotide that is identical to SEQ ID NOs: 162 and 163, and (c) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides that comprise SEQ ID NOs: 162 and 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 162 and 163, respectively. In some embodiments, the kit includes first and second viral vectors comprising the following first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NOs: 164 and 165, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86 of any one of SEQ ID NOs: 164 and 165, respectively. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively; and (b) a first vector or lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 166 and 167, respectively. In some embodiments, the kit includes (a) a first viral vector or lipoplex (e.g., a ribonucleotide) comprising a first polynucleotide comprising SEQ ID NO:210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:210. , LNP), and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO:211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:211.In some embodiments, the kit includes (a) a first viral vector or lipoplex (e.g., a polynucleotide comprising SEQ ID NO:212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:212. , LNP), and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO:213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:213. In some embodiments, the kit includes (a) a first viral vector or lipoplex (e.g., a polynucleotide comprising SEQ ID NO:214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:214. , LNP), and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO:215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:215.In some embodiments, the kit includes (a) a first viral vector or lipoplex (e.g., a polynucleotide comprising SEQ ID NO:216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:216. , LNP), and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO:217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:217. In some embodiments, the kit includes (a) a first viral vector or lipoplex (e.g., a polynucleotide comprising SEQ ID NO:218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:218. , LNP), and (b) a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide comprising SEQ ID NO:219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:219.In some embodiments, the kit includes (a) a first viral vector or lipoplex (e.g., a polynucleotide comprising SEQ ID NO:218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:218. , LNP), and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO:226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:226. In some embodiments, the kit includes (a) a first viral vector or lipoplex (e.g., a polynucleotide comprising SEQ ID NO:225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:225. , LNP), and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO:226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:226.In some embodiments, the kit comprises a composite fusion polypeptide and a vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding the composite fusion polypeptide, wherein the composite fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227. In some embodiments, the kit comprises a composite fusion polypeptide and a vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding the composite fusion polypeptide, wherein the composite fusion polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223. In some embodiments, the one or more fusion polypeptides comprise Gag 54-146, Gag. 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef 149-206, or any polypeptide segment corresponding to these, wherein the amino acid position numbers of Gag, Pol and Nef correspond to SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the one or more fusion polypeptides do not include a polypeptide segment having an amino acid sequence of SEQ ID NOs: 35-47, or a fragment or subsequence thereof, or an amino acid sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 35-47, or a fragment or subsequence thereof. In some embodiments, the kit further comprises one or more unit doses of one or more additional therapeutic agents. In some embodiments, the kit comprises one or more agents that activate latent HIV, such as one or more latency-reactivating agents (LRAs). In some embodiments, the kit comprises one or more LRAs selected from an agonist or activator of one or more Toll-like receptors (TLRs), a histone deacetylase (HDAC) inhibitor, a proteasome inhibitor, a protein kinase C (PKC) activator, a Smyd2 inhibitor, a BET-bromodomain 4 (BRD4) inhibitor, ionomycin, an inhibitor of apoptosis protein (IAP) antagonist, and a second mitochondrial-derived activator of caspases (SMAC) mimetic. In some embodiments, the kit comprises one or more agonists or activators of one or more Toll-like receptors (TLRs). In some embodiments, the TLR agonist or activator is selected from a TLR2 agonist, a TLR3 agonist, a TLR4 agonist, a TLR5 agonist, a TLR7 agonist, a TLR8 agonist, and a TLR9 agonist.In some embodiments, the TLR7 agonist is selected from GS 9620 (vesatolimod), R848 (resiquimod), DS-0509, LHC-165, and TMX-101 (imiquimod), and / or the TLR8 agonist is selected from GS-9688 (sergantolimod), R848 (resiquimod), and NKTR-262 (a dual TLR7 / TLR8 agonist). In some embodiments, the kit comprises one or more interleukin receptor agonists of interleukins selected from IL-2, IL-7, IL-12, and IL-15. In some embodiments, the kit comprises one or more cytokines selected from IL-2, IL-7, IL-12, IL-15, and variants thereof. In some embodiments, the kit comprises one or more innate immune activators. In some embodiments, the one or more innate immune activators comprise an agonist of a receptor selected from fms-related tyrosine kinase 3 (FLT3), stimulator of interferon genes (STING) receptor, DExD / H-box helicase 58 (DDX58, also known as RIG-I), and nucleotide-binding oligomerization domain-containing 2 (NOD2). In some embodiments, the kit comprises an agonist of fms-related tyrosine kinase 3 (FLT3). In some embodiments, the kit comprises one or more antagonists or inhibitors of inhibitory immune checkpoint proteins or receptors, and / or one or more activators or agonists of stimulatory immune checkpoint proteins or receptors. In some embodiments, the one or more immune checkpoint proteins or receptors are selected from CD27, CD70; CD40, CD40LG; CD47, CD48(S). LAMF2), transmembrane domain and immunoglobulin domain-containing 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain-containing T-cell activation inhibitory factor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H Long-Term Receptor-Associated 2 (HHLA2, B7H7); inducible T-cell costimulatory molecule (ICOS, CD278); inducible T-cell costimulatory molecule ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13 B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC class I polypeptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); PVR-related immunoglobulin domain-containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); T cell immunoglobulin and mucin domain-containing 4 (TIMD4; TIM4);Hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activation 3 (LAG3, CD223); signaling lymphocyte activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding UL16-binding protein 1 (ULBP1); UL16-binding protein 2 (ULBP2); UL16-binding protein 3 (ULBP3); retinoic acid early transcript 1E (RAET1E; ULBP4); retinoic acid early transcript 1G (RAET1G; ULBP5); retinoic acid early transcript 1L (RAET1L; ULBP6); lymphocyte activation 3 (CD223); killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR, CD158E1) killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); killer cell lectin-like receptor C2 (KLRC2, CD159c, NKG2C); killer cell lectin-like receptor C3 (KLRC3, NKG2E); killer cell lectin-like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin-like receptor, one Ig domain, and a long cytoplasmic tail 2 (K killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL1); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 2 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor D1 (KLRD1); and SLAM family member 7 (SLAMF7). In some embodiments, the kit comprises one or more blockers or inhibitors of one or more T cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the T cell inhibitory immune checkpoint proteins or receptors are selected from CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273);Programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte-associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain-containing T-cell activation inhibitory factor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); PVR-related immunoglobulin domain-containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activation 3 (LAG 3, CD223); Hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); Galectin 9 (LGALS9); Killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); Killer cell immunoglobulin-like receptor, one Ig domain and long cytoplasmic tail 2 (KIR2DL1); Killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); Killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 2 (KIR2DL3); and Killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1). In some embodiments, the kit comprises one or more agonists or activators of one or more T cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the T cell stimulatory immune checkpoint protein or receptor is CD27, CD70; CD40, CD40LG; inducible T cell costimulatory molecule (ICOS, CD278); inducible T cell costimulatory molecule ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1);poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). In some embodiments, the kit further comprises one or more blockers or inhibitors of one or more NK cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the NK cell inhibitory immune checkpoint protein or receptor is selected from killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, one Ig domain, and long cytoplasmic tail 2 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 2 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); and killer cell lectin-like receptor D1 (KLRD1, CD94). In some embodiments, the kit comprises one or more agonists or activators of one or more NK cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the NK cell stimulatory immune checkpoint protein or receptor is CD16, CD226 (DNAM-1); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314);and SLAM family member 7 (SLAMF7). In some embodiments, the one or more immune checkpoint inhibitors comprise a protein inhibitor of PD-L1 (CD274), PD-1 (PDCD1), or CTLA4. In some embodiments, the kit comprises an antibody that binds to CTLA4. In some embodiments, the protein or antibody inhibitor of CTLA4 is selected from ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, C G-0161, ATOR-1144, PBI-5D3H5, FPT-155(CTLA4 / PD-L1 / CD28), PF-06936308(PD-1 / CTLA4), MGD-019(PD-1 / CTLA 4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4), and AK-104 (CTLA4 / PD-1). In some embodiments, the proteinaceous inhibitor of PD-L1 (CD274) or PD-1 (PDCD1) is selected from the group consisting of pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-1 0, MGA-012, BI-754091, AGEN-2034, JS-001 (toripalimab), JNJ-63723283, genolimuzumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210 (camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306, (MSB0010718C), CX-072, CBT-502, TSR-042 (dostarlimab), MS; B-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 Mab), HLX-20, KL-A167, STI-A1014, STI-A1015(IMC-001), BCD-135, FAZ-053, TQB-24 50, MDX1105-01, FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-01 3(PD-1 / LAG-3), FS-118(LAG-3 / PD-L1)MGD-019(PD-1 / CTLA4), KN-046(PD-1 / CTLA4 ), MEDI-5752 (CTLA4 / PD-1), RO-7121661 (PD-1 / TIM-3), XmAb-20717 (PD-1 / CTLA4), AK-104 (CTLA4 / PD-1), M7824 (PD-L1 / TGFβ-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM3 / PDL1), and INBRX-105 (4-1BB / PDL1). In some embodiments, the one or more immune checkpoint inhibitors are selected from CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD-1). ), or a small molecule inhibitor of CTLA4. In some embodiments, the small molecule inhibitor of CD274 or PDCD1 is selected from GS-4224, GS-4416, INCB086550, and MAX10181. In some embodiments, the small molecule inhibitor of CTLA4 comprises BPI-002. In some embodiments, the kit further comprises one or more antiviral agents. In some embodiments, the one or more antiviral agents are selected from an HIV protease inhibitor, an HIV reverse transcriptase inhibitor, an HIV integrase inhibitor, an HIV non-catalytic site (or allosteric) integrase inhibitor, an HIV entry (fusion) inhibitor, an HIV maturation inhibitor, and a capsid inhibitor.

[0016] Further provided are methods for eliciting an immune response against human immunodeficiency virus (HIV) in a subject in need of such treatment, comprising administering to the subject a fusion polypeptide, multiple fusion polypeptide, polynucleotide, vector, lipoplex (e.g., LNP), or immunogenic composition described herein. Also provided are methods for treating or preventing human immunodeficiency virus (HIV) in a subject in need of such treatment, comprising administering to the subject a fusion polypeptide, multiple fusion polypeptide, vector, lipoplex (e.g., LNP), or immunogenic composition described herein. In some embodiments, the method involves administering a single vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide. In some embodiments, two or more fusion polypeptides, two or more multiple fusion polypeptides, two or more polynucleotides encoding fusion polypeptides, two or more viral expression vectors comprising polynucleotides encoding fusion polypeptides, two or more lipoplexes (e.g., LNP), or two or more immunogenic compositions described herein are administered to the subject simultaneously or in parallel. In some embodiments, the two or more fusion polypeptides, or two or more polynucleotides encoding fusion polypeptides, or two or more viral expression vectors are in the form of a bivalent antigen composition. In some embodiments, the methods involve administering a first fusion polypeptide and a second fusion polypeptide, one or more polynucleotides encoding the first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, or one or more lipoplexes (e.g., LNPs), wherein the first and second polypeptides comprise, in N-terminal to C-terminal order, the following polypeptide segments, optionally linked or connected by one or more linkers: SEQ ID NOs: 6, 4, 16, and 26, and SEQ ID NOs: 7, 5, 27, and 17; SEQ ID NOs: 12, 24, 8, and 10, and SEQ ID NOs: 9, 25, 13, and 11; SEQ ID NOs: 14, 22, 18, 24, and 20, and SEQ ID NOs: 15, 25, 19, 23, and 21; SEQ ID NOs: 26, 16, 4, and 6, and SEQ ID NOs: 7, 27, 5, and 17; SEQ ID NOs: 8, 24, 12,and 10, and SEQ ID NOs: 13, 25, 9, and 11, SEQ ID NOs: 22, 24, 14, 18, and 20, and SEQ ID NOs: 25, 23, 15, 21, and 19, SEQ ID NOs: 20, 6, 4, 18, 16, and 26, and SEQ ID NOs: 7, 19, 5, 21, 27, and 17, SEQ ID NOs: 8, 24, 14, 12, 22, and 10, and SEQ ID NOs: 9, 13, 25, 23, 15, and 11, SEQ ID NOs: 18, 26, 20, 4, 6, and 16, and SEQ ID NOs: 7, 21, 17, 5, 27, and 19, SEQ ID NOs: 22, 24, 12, 14, 8, and 10, and SEQ ID NOs: 15, 25, SEQ ID NOs: 9, 23, 13, and 11, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 7, 21, 5, 25, 33, and 19, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 8, 30, 14, 12, 26, and 10, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 6, 20, 4, 24, 32, and 18, and SEQ ID NOs: 8, 12, 30, 26, 14, and 10, SEQ ID NOs: 7, 21, 5, 25, 33, and 19, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 20, 32, 24, 4, 6, and 18, and SEQ ID NOs: 26, 30, 12, 14, 8, and 10, SEQ ID NOs: 7, 25, 19, 5, 33, and 21, and SEQ ID NOs: 15, 31, 9, 27, 13, and 11, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 20, 10, and 28, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 7, 25, 17, and 19, SEQ ID NOs: 7, 19, 17, and 25, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 24, 16, 6, and 18, and SEQ ID NOs: 27, 11, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NOs: 11, 27, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 22, 6, 20, and 28, and SEQ ID NOs: 23, 7, 21, and 29, SEQ ID NOs: 22, 20, 6, and 28, and SEQ ID NOs: 7, 21, 23, and 29, SEQ ID NOs: 26, 10, 20,and 28, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26, and 10, or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29, and 11. In some embodiments, the methods involve administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, one or more lipoplexes (e.g., LNPs), wherein the one or more fusion polypeptides comprise or consist of the amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227. In some embodiments, the methods involve administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, one or more lipoplexes (e.g., LNPs), wherein the one or more fusion polypeptides comprise or consist of the amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223. In some embodiments, the method comprises preparing one or more polynucleotides, one or more vectors, or one or more lipoplexes (e.g.,LNPs): SEQ ID NOs: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70 and 71, respectively; SEQ ID NOs: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 72 and 73, respectively. fusion polypeptides that are 3%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 74 and 75, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 78 and 79, or to any one of SEQ ID NOs: 78 and 79, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 80 and 81, or to any one of SEQ ID NOs: 80 and 81, respectively; fusion polypeptides, SEQ ID NOs: 82 and 83, which are 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively; or fusion polypeptides, SEQ ID NOs: 84 and 85, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively; SEQ ID NOs: 86 and 87; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 86 and 87, respectively. fusion polypeptides, SEQ ID NOs: 82 and 85, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a given fusion polypeptide, SEQ ID NOs: 82 and 85, or any one of SEQ ID NOs: 82 and 85, respectively; , 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 86, or fusion polypeptides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; fusion polypeptides that are 0%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 83 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 87, respectively;fusion polypeptides that are 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 88 and 87, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87% to any one of SEQ ID NOs: 88 and 87, respectively; , 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 84 and 88, or fusion polypeptides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; , 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, or fusion polypeptides SEQ ID NOs: 90 and 91, or SEQ ID NOs: 90 and 91 that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 101, respectively. 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 92 and 93, respectively. , SEQ ID NOs: 94 and 95, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 95, respectively; SEQ ID NOs: 96 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to any one of SEQ ID NOs: 96 and 97, respectively;Fusion polypeptides that are 98% or 99% identical, SEQ ID NOs: 94 and 96, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94 and 96, respectively, SEQ ID NOs: 95 and 97, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 95 and 97, respectively. fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 220 and 221, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 98 and 100, respectively; fusion polypeptides, SEQ ID NOs: 99 and 101, which are 1%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; or fusion polypeptides, SEQ ID NOs: 98 and 99, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 99 and 101, respectively; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 98 and 99, respectively; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 99% identical to any one of SEQ ID NOs: 100 and 101, respectively;In some embodiments, the method involves administering one or more vectors or one or more lipoplexes (e.g., LNPs) that include one or more polynucleotides encoding the following first and second fusion polypeptides, in N-terminal to C-terminal order, optionally linked or connected by one or more linkers: SEQ ID NOs: 70 and 71, or at least 80%, 81%, 82%, 83%, 84%, 85%, or 90% identical to any one of SEQ ID NOs: 70 and 71, respectively. fusion polypeptides that are 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 71 and 70, or to any one of SEQ ID NOs: 71 and 70, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 72 and 73, or to any one of SEQ ID NOs: 72 and 73, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 73 and 72, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 73 and 72, respectively; 4 and 75, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 74 and 75, respectively; SEQ ID NOs: 75 and 74, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% identical to any one of SEQ ID NOs: 75 and 74, respectively;Fusion polypeptides that are 98% or 99% identical, SEQ ID NOs: 76 and 77, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 76 and 77, respectively, SEQ ID NOs: 77 and 76, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 77 and 76, respectively fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 78 and 79, or any one of SEQ ID NOs: 78 and 79, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 79 and 78, or any one of SEQ ID NOs: 79 and 78, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 80 and 81, or any one of SEQ ID NOs: 80 and 81, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 81 and 80, or any one of SEQ ID NOs: 81 and 80, respectively; fusion polypeptides, SEQ ID NOs: 82 and 83, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 83, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 83 and 82, respectively; SEQ ID NOs: 84 and 85; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 85, respectively. fusion polypeptides, SEQ ID NOs: 85 and 84, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 84, respectively; fusion polypeptides, SEQ ID NOs: 86 and 87, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95% identical to any one of SEQ ID NOs: 86 and 87, respectively; , 96%, 97%, 98% or 99% identical to SEQ ID NOs: 87 and 86, or fusion polypeptides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 86, respectively; fusion polypeptides at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89, respectively; fusion polypeptides that are 0%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 89 and 88, or fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 89 and 88, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 85, respectively;a fusion polypeptide that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 85 and 82, respectively; fusion polypeptides that are 5%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 86, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; fusion polypeptides that are 5%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 82 and 86, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 82 and 88, or any one of SEQ ID NOs: 82 and 88, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 88 and 82, or any one of SEQ ID NOs: 88 and 82, respectively; fusion polypeptides that are 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 83 and 87, or to any one of SEQ ID NOs: 83 and 87, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 87 and 83, or to any one of SEQ ID NOs: 87 and 83 and fusion polypeptides, SEQ ID NOs: 85 and 87, which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 85 and 87, respectively;or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 85, respectively; SEQ ID NOs: 88 and 87; or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 87, respectively. fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 87 and 88, respectively; fusion polypeptides which are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 84 and 88, respectively; fusion polypeptides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 84, respectively; fusion polype...

Claims

1. A fusion polypeptide comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 94-101, or an amino acid sequence which is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 94-101, wherein the total length of said fusion polypeptide is 550 amino acids or less, and said fusion polypeptide is capable of inducing, promoting or stimulating an immune response in humans.

2. The fusion polypeptide of claim 1 further comprising an N-terminal signal peptide or leader sequence.

3. The fusion polypeptide of claim 1 or 2, wherein the fusion polypeptide is capable of inducing, enhancing or stimulating an immune response against HIV-1 in humans.

4. The fusion polypeptide according to any one of claims 1 to 3, wherein the fusion polypeptide is capable of inducing, promoting or stimulating the proliferation and / or activation of one or more cell types selected from monocyte-derived dendritic cells (DCs), CD8+ T cells and CD4+ T cells.

5. A polynucleotide comprising a nucleic acid sequence encoding one or more fusion polypeptides according to any one of claims 1 to 4.

6. 6. The polynucleotide of claim 5, encoding the fusion polypeptide of claim 1, comprising the nucleic acid sequence of any one of SEQ ID NOs: 130-149 or a nucleic acid sequence that is at least 90% identical to any one of SEQ ID NOs: 130-149.

7. An expression cassette comprising the polynucleotide of any one of claims 5 to 6 operably linked to one or more regulatory sequences.

8. A vector comprising one or more polynucleotides according to any one of claims 5 to 6, or an expression cassette according to claim 7.

9. 9. The vector of claim 8, comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, wherein the first fusion polypeptide comprises the amino acid sequence of SEQ ID NO:98 and the second fusion polypeptide comprises the amino acid sequence of SEQ ID NO:100, or is a fusion polypeptide that is at least 90% identical to any one of SEQ ID NOs:98 and 100, respectively.

10. 9. The vector of claim 8, comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, wherein the first fusion polypeptide comprises the amino acid sequence of SEQ ID NO:99 and the second fusion polypeptide comprises the amino acid sequence of SEQ ID NO:101, or is a fusion polypeptide that is at least 90% identical to any one of SEQ ID NOs:99 and 101, respectively.

11. A first polynucleotide and a second polynucleotide: a) a first polynucleotide comprising SEQ ID NO:140, or a polynucleotide that is at least 90% identical to SEQ ID NO:140; and b) a second polynucleotide comprising SEQ ID NO: 146 or a polynucleotide that is at least 90% identical to SEQ ID NO:

146. The vector of claim 9 .

12. A first polynucleotide and a second polynucleotide: a) a first polynucleotide comprising SEQ ID NO:143, or a polynucleotide that is at least 90% identical to SEQ ID NO:143; and b) a second polynucleotide comprising SEQ ID NO: 149 or a polynucleotide that is at least 90% identical to SEQ ID NO:

149. The vector of claim 10 .

13. The vector according to any one of claims 8 to 12, wherein the vector is a viral vector.

14. The vector of claim 13 , wherein the viral vector is replication-deficient, replication-defective, replication-attenuated or replication-competent.

15. 15. The vector of claim 13 or 14, wherein the viral vector is an arenavirus vector selected from lymphocytic choriomeningitis mammarenavirus (LCMV), Kali mammarenavirus (also known as Pichinde mammarenavirus or Pichinde arenavirus), Guanarito virus (GTOV), Junin virus (JUNV), Lassa virus (LASV), Lujo virus (LUJV), Makupo virus (MACV), Sabia virus (SABV), and Whitewater Arroyo virus (WWAV).

16. 16. The vector of claim 15, wherein the viral vector is an arenavirus vector selected from Lymphocytic Choriomeningitis Mammarenavirus (LCMV) or Kali Mammarenavirus (also known as Pichinde Mammarenavirus or Pichinde Arenavirus).

17. The vector of any one of claims 15 to 16, wherein the arenavirus vector comprises a three segmented genome.

18. A host cell comprising one or more polynucleotides according to any one of claims 5 to 6 or one or more vectors according to any one of claims 8 to 17, with the proviso that said host cell is exclusive of a human cell obtained by in vivo introduction of the one or more polynucleotides or the one or more vectors into a human.

19. An immunogenic composition comprising two or more of the fusion polypeptides of any one of claims 1 to 4, or two or more of the polynucleotides of any one of claims 5 to 6, or two or more of the vectors of any one of claims 8 to 17, and a pharma- ceutically acceptable carrier.

20. First and second viral vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, the first fusion polypeptide and the second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 90% identical to any one of SEQ ID NOs: 98 and 100, respectively; and b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, each of which comprises SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 90% identical to any one of SEQ ID NOs: 99 and 101. The immunogenic composition of claim 19, comprising:

21. First and second viral vectors comprising a first polynucleotide and a second polynucleotide: a) a first vector comprising first and second polynucleotides, each comprising a polynucleotide at least 90% identical to any one of SEQ ID NOs: 139 and 145, or SEQ ID NOs: 140 and 146, or SEQ ID NOs: 139 and 145, or SEQ ID NOs: 140 and 146; and b) a second vector comprising a first and a second polynucleotide, each comprising a polynucleotide at least 90% identical to any one of SEQ ID NOs: 142 and 148, or SEQ ID NOs: 143 and 149, or SEQ ID NOs: 142 and 148, or SEQ ID NOs: 143 and 149. The immunogenic composition of claim 19, comprising:

22. 22. The immunogenic composition of claim 20 or 21, wherein the first and second viral vectors are lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors.

23. 22. The immunogenic composition of claim 20 or claim 21, wherein the first and second viral vectors are Kalimanmarenavirus (also known as Pichindemammarenavirus or Pichindearenavirus) viral vectors.

24. 24. The immunogenic composition of any one of claims 19 to 23, formulated for administration via a route selected from intravenous, intramuscular, intradermal, subcutaneous, intranodal, and intramucosal (e.g. buccal, intranasal, rectal, intravaginal).

25. The immunogenic composition of any one of claims 19 to 24, formulated as a liquid, suspension or emulsion.

26. The immunogenic composition of any one of claims 19 to 24, wherein the composition is lyophilized.

27. A kit comprising one or more unit doses of one or more fusion polypeptides according to any one of claims 1 to 4, or one or more polynucleotides according to any one of claims 5 to 6, or one or more vectors according to any one of claims 8 to 17, or one or more immunogenic compositions according to any one of claims 19 to 26.

28. 28. The kit of claim 27, comprising one or more containers selected from vials, ampoules, and pre-filled syringes.

29. The immunogenic composition according to any one of claims 19 to 26 for treating or preventing human immunodeficiency virus (HIV) in a subject in need thereof.

30. First and second viral vectors comprising one or more polynucleotides encoding the following first and second fusion polypeptides: a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 90% identical to any one of SEQ ID NOs: 98 and 100, respectively; and b) a second viral vector comprising one or more polynucleotides encoding said first and second fusion polypeptides, each comprising SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 90% identical to any one of SEQ ID NOs: 99 and 101. The immunogenic composition of claim 29, comprising:

31. The immunogenic composition of any one of claims 29 to 30, wherein the first and second viral vectors are Lymphocytic Choriomeningitis Mammarenavirus (LCMV) viral vectors.

32. The immunogenic composition according to any one of claims 29 to 30, wherein the first and second viral vectors are Kalimanmarenavirus (also known as Pichindemammarenavirus or Pichindearenavirus) viral vectors.

33. First and second viral vectors comprising a first polynucleotide and a second polynucleotide: a) a first vector comprising first and second polynucleotides, each comprising a polynucleotide at least 90% identical to any one of SEQ ID NOs: 139 and 145, or SEQ ID NOs: 140 and 146, or SEQ ID NOs: 139 and 145, or SEQ ID NOs: 140 and 146; and b) a second vector comprising a first and a second polynucleotide, each comprising a polynucleotide at least 90% identical to any one of SEQ ID NOs: 142 and 148, or SEQ ID NOs: 143 and 149, or SEQ ID NOs: 142 and 148, or SEQ ID NOs: 143 and 149.

30. The immunogenic composition of claim 29, wherein the first and second viral vectors are Kalimanmarenavirus (also known as Pichindemammarenavirus or Pichindearenavirus) viral vectors.

34. The immunogenic composition of any one of claims 29 to 33, wherein the subject is infected with, suspected of being infected with, or at risk of being infected with HIV-1.

35. The immunogenic composition of any one of claims 29 to 34, wherein the fusion polypeptide, the polynucleotide, the vector, or the immunogenic composition is administered via a route selected from intravenous, intramuscular, intradermal, subcutaneous, intranodal and intramucosal.

36. Approximately 10 per dose ３ ~about 10 １２ The immunogenic composition according to any one of claims 29 to 35, characterized in that viral focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or viral particles (vp) are administered.

37. 37. The immunogenic composition of any one of claims 29 to 36 for use in a method comprising a prime-boost regimen comprising administering a priming composition at a first time point and administering one or more boosting compositions at one or more subsequent time points.

38. The prime-boost regimen comprises: 1) a first and a second viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: a) a first viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, the first fusion polypeptide and the second fusion polypeptide comprising SEQ ID NOs: 82 and 86, respectively, or a fusion polypeptide that is at least 90% identical to any one of SEQ ID NOs: 82 and 86; and b) a second viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, the first fusion polypeptide and the second fusion polypeptide comprising SEQ ID NOs: 83 and 87, respectively, or a fusion polypeptide that is at least 90% identical to any one of SEQ ID NOs: 83 and 87. priming with an immunogenic composition comprising: 2) a third and fourth viral vector comprising one or more polynucleotides encoding the following first and second fusion polypeptides, optionally linked or connected by one or more linkers: a) a third viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, respectively, comprising SEQ ID NOs:98 and 100, or a fusion polypeptide that is at least 90% identical to any one of SEQ ID NOs:98 and 100; and b) a fourth viral vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, each of which comprises SEQ ID NOs: 99 and 101, or a fusion polypeptide that is at least 90% identical to any one of SEQ ID NOs: 99 and 101. boosting with an immunogenic composition comprising The immunogenic composition of claim 37, comprising:

39. The prime-boost regimen comprises: 1) a first and a second viral vector comprising the following polynucleotides: a) a first viral vector comprising a first and a second polynucleotide comprising SEQ ID NOs: 150 and 152, respectively, or a polynucleotide that is at least 90% identical to any one of SEQ ID NOs: 150 and 152; and b) a second viral vector comprising a first and a second polynucleotide comprising SEQ ID NOs: 155 and 158, or SEQ ID NOs: 154 and 157, respectively, or at least 90% identical to any one of SEQ ID NOs: 155 and 158, or SEQ ID NOs: 154 and 157. priming with an immunogenic composition comprising: 2) a third and a fourth viral vector comprising the following polynucleotide: a) a third viral vector comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or SEQ ID NOs: 140 and 146, respectively, or at least 90% identical to any one of SEQ ID NOs: 139 and 145, or SEQ ID NOs: 140 and 146; and b) a fourth viral vector comprising a first and a second polynucleotide comprising SEQ ID NOs: 142 and 148, or SEQ ID NOs: 143 and 149, respectively, or at least 90% identical to any one of SEQ ID NOs: 142 and 148, or SEQ ID NOs: 143 and 149. boosting with an immunogenic composition comprising The immunogenic composition according to any one of claims 37 to 38, comprising:

40. The immunogenic composition of any one of claims 37 to 39, wherein the viral vector in the base composition is a Kalimanmarenavirus (also known as Pichindemanmarenavirus or Pichindearenavirus) viral vector and the viral vector in the boosting composition is a Lymphocytic Choriomeningitis Mammarenavirus (LCMV) viral vector.

41. The immunogenic composition of any one of claims 37 to 40, wherein the viral vectors in the base composition and the viral vectors in the boosting composition are replication-attenuated.

Images